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TAU AND NEURODEGENERATION: NEUROIMAGING, GENES, AND BIOMARKERS 
The pathway leading from soluble and monomeric to hyperphosphorylated, 
insoluble and filamentous tau protein is at the center of many human neurodegenerative 
diseases, collectively referred to as tauopathies, such as Alzheimer disease (AD). In this 
report, we discuss the role of neuroimaging, genetics, and biomarkers in better 
understanding the underlying brain changes in tauopathies. In Chapters 1 and 2, we 
review current knowledge of tauopathies, the protein tau and FDG PET studies in AD. In 
Chapter 3, we investigate glucose metabolism using [18F]FDG PET in a family with 
multiple systems tauopathy with presenile dementia (MSTD), a primary tauopathy cause 
by a mutation in MAPT. The results from this study suggest that mutation carriers have 
lower [18F]FDG uptake, which may precede clinical onset. In Chapter 4, we assessed 
brain glucose metabolism using [18F]Fluorodeoxyglucose (FDG) positron emission 
tomography (PET) in individuals with Gerstmann–Sträussler–Scheinker Disease (GSS) 
with the PRNP F198S mutation. The results from this study suggest hypometabolism in 
the cerebellar and striatal regions, which may be preceded by hypermetabolism. This 
chapter also evaluated if [11C]Pittsburgh Compound B (PiB) PET is capable of detecting 
PrP-amyloid in GSS in individuals with the PRNP P102L and F198S mutations. The 
results from this study suggest that [11C]PiB is not suitable for in vivo assessment of PrP-
amyloid plaques in GSS. In Chapter 5, we examine a correlation between two peripheral 
markers of axonal degeneration, plasma tau and neurofilament light (NFL), and MRI. 
The results from this study suggest that plasma NFL may be a more specific marker for 
neurodegeneration relative to plasma tau. In Chapter 6, we attempted to create a tau 
biological network from gene and protein databases and literature search. We identified 
over 150 genes that are related to tau protein or MAPT that are involved in different 
 ix 
biological functions. Overall, the results of this report support the notion that using a 
combination of techniques may help model progression of tau pathology. Future studies 
may establish additional markers that may be used in combination with some of these 
measures as tools for diagnosis and for the evaluation of treatment efficacy in 
therapeutic trials. 
 
Ruben Vidal, Ph.D., Chair  
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Chapter 1: Introduction 
 Tau is a microtubule-associated protein first discovered in 1975 by Weingarten 
and colleagues [1]. Shortly thereafter, tau was discovered to be a mainly axonal 
phosphoprotein [2, 3]. By the mid- to late-1980’s, tau was identified as the core protein in 
the neurofibrillary tangles of Alzheimer’s disease (AD) [4-8]. At first, interest in tau was 
low after it was demonstrated tau pathology was second to amyloid-beta (Aβ) pathology 
in AD. However, in the mid- to late-1990’s, interest in tau skyrocketed when tau 
pathology and mutations were discovered in neurodegenerative diseases with no 
amyloid pathology [9-12]. These diseases became collectively known as frontotemporal 
dementia with parkinsonism linked to chromosome 17 (FTDP-17) [13]. Interestingly, both 
AD and FTDP-17 show tau that is abnormally hyperphosphorylated. Now, several other 
neurodegenerative disorders linked to aggregates of hyperphosphorylated tau in 
neurons and/or glial cells have been identified and are collectively referred to as 
“tauopathies” [14]. 
 
1.1 The Microtubule-Associated Protein Tau 
 
The Tau Gene 
The tau protein is encoded by the microtubule-associated protein tau (MAPT) 
gene. The MAPT gene spans 16 exons and is located at chromosome 17q21 [15]. 
MAPT undergoes alternative splicing of exons 2, 3, and 10, which results in a total of six 
normally expressed isoforms ranging from 352-441 amino acids in the central nervous 
system (CNS). The exclusion or inclusion of exon 10 determines whether the tau protein 
will contain three (3R) or four (4R) repeat microtubule-binding domains, respectively. 
The healthy adult brain has an equal ratio of 3R:4R tau. The presence of the extra 
microtubule-binding repeat increases the affinity of 4R tau isoforms for tubulin [16]. In 
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addition, “big tau” is a tau isoform in peripheral neurons that project very long axons with 
large diameters. Big tau has an extra N-terminal region encoded by exon 4a and is not 
transcribed in the human brain [17, 18].   
Rare mutations in MAPT have been identified as the main causative agent in 
some neurodegenerative disorders, such as some forms of corticobasal degeneration, 
progressive supranuclear palsy, and frontotemporal dementia [9, 19, 20]. Most mutations 
are located in or around exon 10 and promote exon 10 inclusion, thus leading to an 
overproduction of 4R tau isoform. The finding that genetic variations in MAPT may be 
the primary cause of neurodegeneration in these disorders suggests the potential that 
MAPT loci may play a pathogenic role in other neurodegenerative diseases associated 
with tau. However, detecting an association between MAPT and other 
neurodegenerative diseases may be hindered if the genetic variant is rare or if the 
genetic variant interacts with other genetic variants to cause the disease or disease-
associated traits. 
A 900kb inversion covers the MAPT region, generating a 1.8Mb region of linkage 
disequilibrium defined by two major haplotypes, H1 and H2, in individuals of European 
descent [21, 22]. The H1 haplotype contains multiple polymorphisms, exhibits linkage 
disequilibrium, and contains many sub-haplotypes compared to H2, which is a single un-
recombining haplotype. H1 has been linked to familial and sporadic neurodegenerative 
disorders such as progressive supranuclear palsy, corticobasal degeneration, 
Parkinson’s disease, and frontotemporal dementia [9, 22-24].  
 
Tau Protein and Function 
Tau is a natively unfolded protein that is highly soluble due to its hydrophilic 
character. Little secondary structure exists except for β-structure in the R2 and R3 
microtubule binding repeats which enables self-assembly into filaments [25]. The tau 
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protein has four main domains that mediate function: (1) the negatively charged, acidic 
N-terminal domain, which projects away from the negatively charged microtubule and is 
thought to be involved in microtubule spacing; (2) the proline-rich region, which is 
involved in cell signaling; (3) the positively charged microtubule binding repeat region, 
which binds to the inner surface of microtubules and may also play a role in scaffolding 
and signal transduction; and, (4) the C-terminal domain, which regulates microtubule 
polymerization by acting as an electrostatic zipper [1, 26]. Tau also plays a fundamental 
role in several other cellular processes such as axonal elongation and transport and 
neurite polarity.  
 
Sorting Mechanisms of Tau Protein 
Tau is mainly expressed in neurons and is primarily found in neuronal axons in 
the CNS, although small amounts of tau have been identified in the somatodendritic 
compartments and the nucleus [27, 28]. Little is known regarding the sorting mechanism 
of tau but evidence suggests that the distribution could occur at either the mRNA or 
protein level. Tau mRNA has been discovered in axons, and it is thought that transport 
to the axon may be mediated by a 3’ – untranslated region (UTR) axonal localization 
signal [29, 30]. Additionally, preferential translation of tau mRNA in the axon, owing to a 
5’ - UTR terminal oligopyrimine tract, mediates mammalian target of rapamycin-
governed protein synthesis, which is important in regulating the cell cycle [31]. At the 
protein level, it has been hypothesized that tau is degraded faster in non-axonal 
compartments or that tau has a higher affinity for axonal microtubules over dendritic 
microtubules [32]. Furthermore, a retrograde barrier at the axon initial segment was also 
suggested as potential factor keeping tau in the axonal compartment [33].  
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Post-translational Modifications 
Tau protein is heavily regulated by post-translational modifications. Probably the 
most important of these modifications is phosphorylation, which negatively regulates tau 
solubility, cellular distribution, association with microtubules, and interaction with binding 
partners [34]. There are 85 serine, threonine, and tyrosine phosphorylation sites on the 
longest isoform of tau, the majority of which are located around the microtubule-binding 
domains. Phosphorylation of tau is developmentally regulated with high tau 
phosphorylation observed from the embryonic stage through synaptogenesis [35]. Then, 
in the normal adult human brain, tau phosphorylation decreases to approximately 2-4 
mole phosphate attached per molecule of tau.  
Tau is mainly phosphorylated by proline-directed protein kinases (PDPK), 
including glycogen synthase kinase 3 beta, cyclin-dependent kinase 5, and mitogen 
activated protein kinases, but several non-PDPK, such as calcium/calmodulin-dependent 
kinase II and protein kinase C, also phosphorylate tau [36-39]. Tau dephosphorylation is 
mainly regulated by phosphatases; protein phosphatase 2A accounts for about 70% of 
tau phosphatase activity [40]. Additionally, tau conformation can affect phosphorylation 
[41].  
Tau protein can also undergo several other post-translational modifications 
including ubiquitination, glycosylation, acetylation, methylation, nitration, isomerization, 
sumoylation, and truncation [42]. The phosphorylation of tau can be influenced by other 
post-translational modifications. For example, O-GlcNAcylation, a type of O-
glyocsylation, attaches O-linked β-N-acetylglucosamine (O-GlcNAc) to some 
seronine/threonine phosphorylation sites of tau [43]. Thus, O-GlcNAcylated tau 
competes with the phosphate groups that occupy the same sites, consequently reducing 
tau phosphorylation at this location. Abnormal post-translational modifications to tau 
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usually enhance or suppress phosphorylation, promote or prevent tau aggregation, or 
alter tau conformation, contributing to the pathological state of tau. 
 
Tau Aggregation 
      The exact trigger for tau aggregation is unknown. Tau function is tightly regulated 
by phosphorylation, and hyperphosphorylation of tau leads to microtubule destabilization 
and missorting of tau into the somatodendritic compartment [44]. The 
hyperphosphorylated tau then undergoes a conformational change enabling self-
assembly into filaments. Polymerization of tau forms paired helical filaments (PHF) or 
straight filaments (SF), with the core of each composed of the microtubule-binding 
repeats. Tau in solution forms a “paperclip” conformation where the C-terminus is folded 
onto the microtubule-binding repeat domain, and the N-terminus is folded over the C-
terminus. This conformation is thought to prevent aggregation since the microtubule-
binding repeats are less accessible [45]. Abnormal hyperphosphorylation in the N- and 
C-terminus cause the “paperclip” confirmation to loosen, thus exposing the microtubule-
binding repeats for aggregation, forming the PHF/SF core [46]. PHF and SF further 
aggregate to form neurofibrillary tangles (NFT) or neuropil threads that are characteristic 
of several tauopathies. Biochemically, tau aggregates can be composed of an equal 
ratio of 3R:4R, 4R>>3R, or 3R>>4R.  
While it has yet to be determined if abnormal phosphorylation alone triggers tau 
aggregation, it is likely that cofactors or interactions with other molecules also have an 
effect. Even so, destabilization of microtubules and the subsequent impairment of axonal 
transport due to tau hyperphosphorylation appear to be the critical steps leading to 
neuronal demise. After tangle-bearing cells die, the tangles remain in the extracellular 
space as “ghost tangles.” While NFTs have been strongly correlated with dementia and 
neurodegeneration [47], relatively new evidence suggests that tau toxicity does not 
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require the formation of fibrillar tau. Instead, several reports have proposed prefibrillar 
oligomeric tau as the toxic tau species, which were detected and isolated in the early 
stages of aggregation [48].   
The presence of NFTs does not necessarily indicate dementia or disease. 
Pathological studies have consistently shown tau pathology in cognitively healthy young 
and older adults [49-51]. In general, tau pathology restricted to subcortical regions in the 
absence of amyloid pathology was associated with normal aging and was termed 
primary age-related tauopathy (PART) [52]. On the other hand, tau pathology found 
outside subcortical regions is usually associated with cognitive impairment and disease. 
 
Propagation of Tau 
Similar to the mechanism of tau sorting, little is known regarding the process by 
which physiological and pathophysiological tau spreads. While tau is mainly an 
intracellular protein, new reports suggest that tau can spread via synaptic and non-
synaptic mechanisms. For example, exosomal and ectosomal tau release has been 
observed [53]. Additionally, synaptic stimulation was shown to enhance tau release to 
the extracellular space, as measured in brain interstitial fluid [54, 55]. Current research 
also suggests tau pathology may spread through the brain in a prion-like manner, 
inducing tau fibrillization cell-to-cell and in anatomically connected brain regions, which 
could also be mediated by tau oligomers [56-60]. The pattern by which tau pathology 
progresses is highly disease-specific.  
 
Tauopathy Classification  
     Sporadic and familial tauopathies are quite heterogeneous and can be classified 
by clinical, neuropathological, and biochemical characteristics. For example, when tau 
pathology is the salient neuropathological insult, the disorder is classified as a “primary 
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tauopathy.” When tau pathology is associated with another pathology, as seen in AD, 
the disorder is classified as a “secondary tauopathy.” Tau pathology can also be 
classified according to the predominant tau isoform. Class I tauopathies include all six 
tau isoforms and can have an equal ratio of 3R:4R, including AD and some cases of 
FTDP-17 [61-63]. Class II and Class III tauopathies are predominantly composed of 4R 
tau isoforms and 3R tau isoforms, respectively [9, 64]. Finally, Class IV tauopathy is 
represented by a disease called myotonic dystrophy which excludes exons 2, 3, and 10 
[65].  
 
1.2 Primary and Secondary Familial Tauopathies 
Primary familial tauopathies are caused by an autosomal-dominant mutation in 
the tau gene (MAPT) [66]. The majority of these are FTDP-17 diseases. The tau 
mutations in FTDP-17 are either missense, deletion, or silent mutations in the regions 
surrounding exon 10 and most of these mutations lead to an increase in the 4R:3R ratio. 
Different tau mutations give rise to variable clinical and neuropathological phenotypes of 
FTDP-17 [67]. Clinical phenotypes can include behavioral changes, psychiatric 
symptoms, cognitive decline, extrapyramidal signs, epilepsy, and/or motor neuron 
disease. Neuropathologically, all tau filaments are hyperphosphorylated. The clinical and 
neuropathological phenotypes of FTDP-17 often overlap with those of Pick disease, 
corticobasal degeneration, or progressive supranuclear palsy [68]. 
Secondary tauopathies can be caused by autosomal-dominant mutations in 
genes other than MAPT. For example, mutations in the prion protein (PrP) gene (PRNP) 
or the integral transmembrane protein 2B (BRI2) gene can also lead to amyloid (APrP 
and ABri respectively) and NFT formation [63, 69]. Additionally, mutations in the 
presenlin-1 (PSEN1), presenlin-2 (PSEN2), and amyloid precursor protein (APP) genes 
lead to Aβ and NFT deposition associated with familial AD (see section 1.3) [70-74]. 
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Interestingly, the tau pathology seen in disorders associated with PRNP and BRI2 
mutations are biochemically and structurally similar to that seen in AD [62, 63, 75, 76]. 
These findings also give credence to the amyloid cascade hypothesis, in which tau 
pathology occurs as a consequence of amyloid pathology [77]. Clinically, these 
mutations present with various phenotypes but commonly exhibit cognitive decline and 
ataxia. Genetic tests allow for accurate diagnosis of these familial tauopathies. 
 
1.3 Alzheimer’s Disease 
The most common tauopathy is AD. AD is a progressive neurodegenerative 
disorder that affects millions of people worldwide that is characterized by a decline in 
memory and cognitive disturbances in multiple domains, including language, orientation, 
and judgment. AD in individuals over the age of 65 is referred to as late-onset AD 
(LOAD) while those under the age of 65 are classified has having early-onset AD 
(EOAD) [78]. More than half of the cases of EOAD are caused by single-gene mutations 
and are termed familial AD. Currently, LOAD can only be diagnosed post-mortem by 
identifying two key pathological features, intracellular NFTs and extracellular Aβ plaques 
[47, 79-83].   
NFTs in AD have both 3R and 4R isoforms of hyperphosphorylated tau protein. 
Although the full relationship between NFTs and AD is not completely understood, 
studies have suggested that initiation of NFTs may be induced by Aβ plaques [84, 85]. 
NFTs spread in a well-defined pattern called Braak stages [47, 86]. Tau pathology is first 
observed in the transentorhinal region (stage 1 and 2), then progresses to the limbic 
regions and the hippocampus (stage 3 and 4), and finally the neocortex (stage 5 and 6). 
NFTs have been consistently correlated with neurodegeneration and cognitive status 
[87, 88].   
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Aβ plaques are a result of the accumulation of an insoluble form of Aβ, a product 
of amyloidogenic processing of APP, and are thought to be the causative pathologic 
agent in AD. The amyloidogenic processing pathway occurs when APP is cleaved by β-
secretase and subsequently cleaved by γ-secretase releasing the amyloidogenic Aβ 
peptide and the N-terminal soluble APPβ [89]. The major β-secretase and rate-limiting 
enzyme responsible for generating the Aβ peptide is the β-secretase APP cleaving 
enzyme (BACE1). When BACE1 was deleted in a mouse model, Aβ was not produced 
making BACE1 a possible therapeutic target for AD [90]. The enzyme responsible for the 
γ-secretase cleavage of APP is the product of PSEN1 and PSEN2, a secondary γ-
secretase. The non-amyloidogenic processing pathway of APP occurs when an α-
secretase cleaves APP within the Aβ domain, therefore eliminating the formation of the 
detrimental form of the protein. Several different Aβ species exist with a great degree of 
heterogeneity at the N- and C-terminus of the peptide. The most abundant species is 
Aβ1-40, while the most neurotoxic but less abundant form is Aβ1-42. Aβ1-42 pathology is 
highest in the frontal cortex but is seen throughout the cortex in AD [91].  
Clinical diagnosis of LOAD is usually a result of exclusion of other dementias.  
Diagnostic criteria for possible, probable, or definite LOAD involves a combination of 
medical history, clinical examination, neuropsychological testing, and other laboratory 
assessments [78]. However, the sensitivity and specificity for these methods are 
relatively low and diagnostic accuracy rates are ≤90%. In an attempt to predict those 
most likely to be diagnosed with LOAD, researchers and clinicians have defined a 
transitional state between normal aging and dementia, referred to as mild cognitive 
impairment (MCI) [92]. Individuals may be diagnosed with MCI if they present with 
cognitive complaints from the individual, an informant, or a clinician and abnormal age-
adjusted memory or other cognitive domain performance, but proceed with normal daily 
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activities and are non-demented. Individuals with MCI are at high risk for LOAD, with a 
conversion rate of up to 15% per year [92].  
Mutations within AD-related genes contribute to the majority of familial EOAD 
cases. As previously mentioned, mutations within the gene responsible for Aβ 
production, APP, and other genes that encode enzymes that cleave within the APP 
gene, PSEN1, and PSEN2 contribute to EOAD [71, 72]. However, no such gene 
mutations have been identified in patients with LOAD. Although mutations within MAPT 
have been identified and are the main causative agent in other neurodegenerative 
disorders as described in sections 1.1 and 1.2, none thus far have been associated with 
AD. Currently, the only gene with a high risk association to LOAD is the apolipoprotein E 
(APOE) gene, and more specifically, the ε4 allele of APOE [93].  Subjects that are ε4 
positive for both alleles are eight times more likely to develop AD than those with the ε2 
and ε3 genotypes, thus increasing risk for AD from 20% to 91% [93].   
Recent advances in molecular genetics, such as linkage studies and genome 
wide association studies (GWAS), have identified several other candidate genes which 
are associated with LOAD risk; however, their combined predictive value remains quite 
low (for review see [94]). More recently, studies have had success with finding new 
genetic risk factors associated to AD-related phenotypes rather than just disease 
presence or absence, which was historically the primary outcome variable used in most 
genetic studies [95-97]. Using biomarkers of AD pathology (tau and Aβ) increases the 
power of genetic studies for identifying novel genes and improves the biological 
interpretability of the potential effect of identified genetic variants. Identification of this 
class of biomarker based genotype-phenotype association is likely to provide clues to 
the pathogenesis of AD, help identify potential novel therapeutic targets, and aid in the 
early detection and clinical diagnosis of AD.   
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1.4 Neuroimaging 
Great effort has been put forth to develop methods to study neuronal insults and 
proteinopathies in the living brain. The development of noninvasive neuroimaging 
techniques to study structural, functional, and molecular alterations in disease has 
allowed for the development of hypothetical models to describe the ongoing series of 
brain changes that may occur over decades and exist well before symptoms appear in 
neurodegenerative diseases [98]. These findings have given scientists new insight into 
the development of neurodegenerative diseases and provided supportive evidence to 
improve diagnosis.  
Today, advances in neuroimaging continue to provide invaluable information 
about the largely unknown mechanisms and order of pathological progression underlying 
tauopathies. Different imaging modalities can facilitate early and accurate differential 
diagnosis to ensure proper treatment and are commonly used by both clinicians and 
researchers. 
 
Structural Imaging 
 Magnetic resonance imaging (MRI) uses a magnetic field to align the nuclei of 
protons in the body (for review see [99, 100]). The MR machine then sends radio 
frequency pulses that stimulate the hydrogen protons, causing them to spin in a different 
direction from the magnetic field. Once the radio frequency pulse is turned off, the MRI 
sensors are able to detect the energy released as the protons return to their normal 
position. This information is sent to a computer and complex mathematical formulas 
convert the energy to a 3D image. Protons in different tissues spin at different rates, thus 
the scanner is able to differentiate between tissue types.  
 Loss of brain volume, primarily due to decreased synaptic density or neuronal 
loss, is a key feature in several tauopathies. For this reason, structural MRI of the brain 
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has been used as a targeted technique to observe brain shrinkage [101, 102]. The 
atrophy observed by MRI can be used to identify focal atrophic patterns specific to one 
neurodegenerative disease relative to another. There is usually some overlap in atrophy 
between disease and controls, and between diseases themselves, thus structural MRI is 
not a conclusive measure in the diagnostic process. Still, the atrophic patterns may be 
useful in differentiating, predicting, or monitoring disease status. For example, regional 
brain atrophy begins early in AD and correlates strongly with cognitive decline [103-105]. 
Assessments using structural MRI have found that atrophy within AD patients begins in 
the entorhinal cortex, spreads to the hippocampus, parahippocampal gyrus, and 
amygdala, and then further extends to the parietal and frontal lobes, similar to the 
pathological findings of NFT deposition in post-mortem brains [47, 106-108]. 
 
Molecular Imaging 
 In addition to MRI measures, positron emission tomography (PET) can give 
important and essential information about molecular changes in the living brain. PET is a 
nuclear medicine technique that introduces trace amounts of drugs tagged with a 
radioisotope (“tracers”; for review see [109]). The amount of tracer uptake is detected by 
a PET camera, enabling qualitative and quantitative assessment of brain function (e.g., 
glucose metabolism, neurotransmitter activity), proteinopathy burden (e.g., Aβ, tau), 
microglial activation, and astrocytes.  
 PET imaging begins with injection of a radioactive tracer (“radiotracer”), usually 
intravenously. Either upon injection or after a short time of allowing uptake of the injected 
radiotracer into the target organ such as the brain, the patient is placed in the circular 
center of the PET detectors. The radiotracer begins to decay, emitting positrons. 
However, emitted positrons can only travel a small distance before encountering an 
electron. The meeting of the positron and electron will cause an annihilation event, 
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generating two 511 keV gamma rays (“photons”) to be emitted at directions 180° from 
one another. The gamma rays are then detected by two opposing scintillator crystals in 
the PET scanner. Two annihilation photons that are registered within a short period of 
time (3-15 nanoseconds) is called a “coincidence.” The coincidence events are collected 
and stored by the PET scanner and later reconstructed through back-calculation of the 
origin of the photons to create images. Indirect mapping of functional processes is then 
assessed from these images for prognostic, diagnostic, and research purposes. 
 The most commonly used PET tracer, which is an important oncological marker 
in addition to being used in neurologic studies, is [18F]fluoro-2-deoxy-D-glucose (FDG).  
[18F]FDG PET is used to detect cerebral metabolic rates of glucose, the brain’s only 
source of energy. After uptake, [18F]FDG is phosphorylated by hexokinase. The 
phosphorylated [18F]FDG does not undergo further metabolism and becomes trapped in 
neurons, allowing for the measurement of the glucose metabolic rate. Cerebral glucose 
metabolism is decreased in several tauopathies generally due to synaptic dysfunction 
and neural degeneration. Thus, [18F]FDG serves as a surrogate marker for neural 
activity and is potentially capable of detecting dysfunction before structural changes 
occur. [18F]FDG PET has proven to be a useful tool for the differential diagnosis of AD 
from other dementias and cognitively normal individuals, as well as for prediction of 
disease course (for review, see [110]). 
 The introduction of in vivo Aβ PET tracers has provided new and invaluable 
insight into our understanding of the underlying pathophysiological processes of 
amyloidogenic neurodegenerative disorders. Over the past 15 years, several amyloid 
tracers have been developed and are available for research use but only three have 
been approved by the US Food and Drug Administration (FDA) – [18F]florbetapir (AV-45, 
Amyvid), [18F]florbetaben (BAY94-9172, NeuraCeq), and [18F]flutemetamol (GE067, 
Vizamyl) – and are available for clinical use [111-113]. The most widely utilized research 
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tracer is [11C]Pittsburgh Compound B (PIB) and retention of [11C]PIB highly correlates 
with amyloid pathology post-mortem [114]. However, it is not widely used in clinic due to 
its short half-life of carbon-11 [115].  
 Extensive effort has been made to develop PET tracers that can help to visualize 
PHF-tau deposition in vivo. Accordingly, several tau ligands have been developed, 
although none have yet to be completely validated as superior or FDA approved. 
However, several of these tracers showed low specificity for tau or high white matter 
retention, leading to inaccurate interpretation. There is currently one tau-specific tracers 
in phase 2 research, [18F]Flortaucipir (also known as AV-1451 and T807). AV-1451 
shows more than a 25-fold selectivity for PHF-tau over Aβ and demonstrates low white 
matter binding, providing a high grey-white matter contrast [116]. Post-mortem studies 
further validate AV-1451 as a strong binder of PHF-tau, but suggest that the tracer may 
not be suitable for other tau species [117]. 
 
1.5 Biofluid Markers 
Biofluid markers offer an alternative quantitative analysis of brain pathology. 
Proteins found in the brain interstitial fluid can be interchanged with the biofluids 
cerebrospinal fluid (CSF) and blood through the blood- and CSF-brain barriers. These 
biofluids contain proteins that may reflect physiological processes and pathological 
changes. These measures of proteins known to be abnormal in disease provide an 
estimate of protein concentration that track disease progression over time, and increase 
diagnostic accuracy, amongst several other contexts of use. The field is rapidly evolving 
with new, high sensitivity assays in development.   
 
 
 
 15 
Cerebrospinal Fluid Markers 
CSF has the closest proximity to the brain interstitial fluid and thus offers the 
most direct way to measure biochemical changes that occur in the brain, making CSF an 
important biomarker of disease.  
Research into CSF markers that reflect the pathological processes of disease 
have been fruitful. CSF measurements of total tau (t-tau), tau phosphorylated at 
threonine 181 (p-tau), and Aβ1-42 were some of the earliest markers investigated [118, 
119]. Since then, other candidate markers for neurodegeneration, such as neurofilament 
light chain (NFL, a marker of axonal neurodegeneration) and neurogranin (a 
postsynaptic markers expressed in dendritic spines), have been investigated [120].  
Alterations in CSF measures of amyloid and tau in tauopathies, especially AD, 
have been heavily investigated. Individuals with AD express higher CSF levels of t-tau, 
p-tau, and low levels of Aβ1-42 [121, 122]. The high tau levels are thought to be a 
reflection of neuron death and a resulting release of tau into the interstitial fluid, while the 
low CSF levels of Aβ1-42 are possibly due to aggregation of amyloid into neuritic plaques 
and thus, reduction in “free” amyloid that is not bound to plaques in the interstitial fluid. 
Combining amyloid and tau markers into t-tau/Aβ1-42 and p-tau/Aβ1-42 ratios has been 
shown to be able to differentiate AD and MCI from controls [122]. The effect of non-AD 
and familial neurodegenerative diseases on CSF tau levels is less clear [123-125]. 
Results between studies are highly inconsistent suggesting the use of CSF tau in 
diseases other than AD may have little diagnostic value per se, but may aid in disease 
differentiation, particularly from AD. 
 
Blood-based Markers 
Contrary to neuroimaging and CSF collection, blood-based biomarkers are 
minimally invasive and offer a more time- and cost-effective option to detect and track 
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disease pathology. Additionally, peripheral biomarkers easily allow for repeated 
collection in a short period of time. The discovery of a peripheral biomarker for 
tauopathies would substantially alter the field by offering an easily obtainable first-line 
screening tool that could be used for disease detection, diagnosis, risk assessment, and 
monitoring response to therapeutics, for example. One of the biggest challenges in using 
blood-based biomarkers for disease detection is the complex composition of proteins 
that are constitutively present in the blood. However, there have been new 
developments in ultra-sensitive assays that are capable of detecting proteins, including 
tau and NFL, at extremely low concentrations [126, 127]. Plasma levels of tau protein 
have been shown to be significantly elevated in AD and traumatic brain injury [21, 128]. 
Furthermore, plasma NFL has also recently been associated with AD and progressive 
supranuclear palsy [129, 130]. Plasma Aβ has also been investigated in AD but studies 
have consistently reported no significant difference between disease and controls [131].  
 
1.6 Statement of Purpose 
 Great heterogeneity is observed in sporadic and familial tauopathies, both 
clinically and pathologically. While familial dementias have been well clinically defined 
and a causative mutation identified, characterization of disease progression at the 
molecular level is needed to better understand the underlying brain changes leading to 
disease phenotype. For sporadic tauopathies, it is likely that multiple genes with small 
effect sizes contribute to overall disease risk. Furthermore, there is a need for peripheral, 
non-invasive biomarkers that can accurately represent brain injury in these 
neurodegenerative disorders. Accordingly, the goals of this work were as follows: 
 1. Using PET imaging, identify disease-specific glucose metabolic patterns in 
primary and secondary familial tauopathies, specifically multiple systems tauopathy with 
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presenile dementia (MSTD) and Gerstmann–Sträussler–Scheinker (GSS) disease, 
respectively, to better define the molecular changes in these diseases. 
 2. Investigate the association of plasma tau and plasma NFL, markers of axonal 
degeneration, with grey matter density measured on MRI in order to evaluate these 
blood-based proteins as suitable markers of neurodegeneration in Alzheimer’s disease.   
 3. Develop a tau biological network curated from gene and protein databases 
and literature review to offer an alternative method to investigate the genetic contribution 
of tau-related genes to tauopathies.   
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Chapter 2: Review of [18F]FDG PET in Alzheimer’s Disease 
2.1 Introduction 
 Selection of appropriate imaging modalities, in combination with other 
established biomarkers, can further our knowledge regarding the temporal and spatial 
patterning of protein deposition and neuronal function in neurodegenerative disorders. 
This chapter will provide an overview of the major findings from [18F]fluoro-2-deoxy-D-
glucose (FDG) positron emission tomography (PET) studies of patients across the 
spectrum of late-onset Alzheimer’s disease (LOAD). 
 
2.2 Metabolic Patterns in AD  
Relative to cognitively normal controls (CN), AD patients show glucose 
hypometabolism in regions of the temporoparietal cortex, medial temporal lobe (MTL), 
posterior cingulate, and precuneus, with frontal involvement in more advanced AD 
(Figure 1A). These regions were confirmed in a meta-analysis of 16 FDG PET studies, 
suggesting they show a robust reduction in glucose metabolism in AD [132]. The earliest 
metabolic changes in AD are seen in the posterior cingulate cortex [133]. The 
cerebellum, anterior cingulate, striatum, thalamus, primary sensorimotor and visual 
cortices are relatively spared until late in the disease. In comparison, early-onset AD 
(EOAD) shows greater hypometabolism in the parietal and frontal regions compared to 
LOAD [134]. Asymptomatic familial AD patients with mutations in APP, PSEN1, or 
PSEN2 show similar metabolic patterns to LOAD, providing evidence for the importance 
of these brain regions in AD [135]. Of note, there is no significant effect of apolipoprotein 
E (APOE) ε4 status on glucose metabolic levels in AD, with no difference in [18F]FDG 
uptake between AD patients who are APOE ε4 carriers relative to non-carriers [136]. 
The regional hypometabolic patterns observed in AD have been highly reproducible 
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suggesting that the observed [18F]FDG pattern is specific to AD and therefore could be 
helpful in diagnosis and differentiation from other dementias.  
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Figure 1. [18F]FDG uptake across the Alzheimer’s disease spectrum.  
(A) Difference in [18F]FDG PET uptake between Alzheimer’s disease (AD) vs 
cognitively normal controls (CN), and (B) mild cognitive impairment (MCI) vs CN. (C) 
Glucose metabolic pattern in CN subjects only. Voxel-wise image analysis was done 
using standard VBM methods in SPM8 with results displayed at p<0.05 (FWE corrected) 
and a minimum cluster size (k) = 100 voxels. R = right; L = left. 
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2.3 Metabolic Patterns in Mild Cognitive Impairment 
Although a heterogeneous pattern is often found, mild cognitive impairment 
(MCI) participants predominantly show reduced glucose metabolism in the posterior 
cingulate and hippocampus (Figure 1B) [137].  Additionally, APOE ε4 carriers with MCI 
show lower glucose metabolism in the typical AD-related regions compared to non-
carriers [138].  
Further, since the same regions that are hypometabolic in AD show 
hypometabolism in MCI, [18F]FDG may also be useful for predicting MCI progression to 
AD. For example, longitudinal studies of MCI have suggested that MCI participants who 
later converted to AD showed a significant reduction in [18F]FDG uptake in AD-specific 
hypometabolic regions compared to non-converters prior to conversion, supporting 
[18F]FDG as an effective tool for tracking AD progression. A review by Perani et al. 
discussed several studies in which quantitative measures allowed for derivation of a cut-
off score to discriminate and predict converters from non-converters with sensitivity and 
specificity greater than 78% [139]. These findings suggest that decreased glucose 
metabolism in the typical AD-specific regions precedes the onset of AD symptoms and 
may be a predictor of MCI to AD progression.  
 
2.4 Metabolic Patterns in CN 
Neuronal integrity can be somewhat compromised during normal aging (Figure 
1C) [140]. In general, a global decrease in glucose metabolism is correlated with 
increasing age. The most affected regions are the medial and orbital prefrontal, anterior 
cingulate, and motor cortices. Healthy individuals who are APOE ε4 carriers show 
hypometabolism in the parietotemporal cortex, posterior cingulate, and precuneus, which 
are also affected in MCI and AD [141]. Interestingly, recent studies have noted that CN 
participants with a maternal history of AD also show metabolic patterns consistent with 
 22 
AD [142]. These findings suggest that the regional hypometabolic changes in preclinical 
AD participants that mirror the hypometabolism seen in AD (although to a lesser extent) 
may precede the onset of clinical and cognitive symptoms. Indeed, [18F]FDG PET can 
predict CN conversion to MCI or AD, with CN-converters showing reduced glucose 
metabolism particularly in the temporal, frontal, and parietal cortices compared to CN-
stable [143].  
 
2.5 Associations Between Metabolic Patterns and Neuropsychological Patterns  
Glucose metabolism is associated with cognition across the AD spectrum. A 
positive association between better executive function and increased glucose 
metabolism in the occipital, temporal, and parietal cortices was observed in AD and MCI 
[144]. Memory performance also showed an association with glucose metabolism with 
higher (better) test scores associated with increased [18F]FDG in frontal regions for AD 
and in the precuneus and posterior cingulate cortex in MCI. Longitudinal studies 
demonstrated that MCI participants with abnormal hypometabolism had worse 
neuropsychological test scores and declined at a faster rate than MCI participants with 
normal glucose metabolism [145]. Furthermore, longitudinal studies of the CN individuals 
reported that reduced MTL, parietal, and hippocampal glucose metabolism are 
associated with a faster decline in cognitive function. These observations suggest that 
changes in glucose utilization mirror the cognitive deterioration that occurs during the 
progression of AD and further support the use of [18F]FDG in the clinical research and 
diagnosis of AD. 
 
2.6 Differential Diagnosis 
Different neurodegenerative disorders can affect different brain regions 
producing disease-specific metabolic patterns. Identifying these areas with lower 
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metabolism can thus aid in differentiating dementias, especially in the early stages. 
[18F]FDG PET can discriminate AD from controls with high sensitivity and specificity, 
leading to improved diagnosis. Similarly, studies have also shown that [18F]FDG PET 
can distinguish AD from frontotemporal lobar degeneration (FTLD) and dementia with 
Lewy bodies (DLB) with sensitivity as high as 99% and specificity as high as 98%, in 
addition to other non-AD dementias [139]. DLB shares similar symptoms and 
hypometabolic brain regions with AD, thus making it difficult for clinicians to accurately 
distinguish the two. However, it has been noted that DLB patients present with more 
significant occipital hypometabolism relative to AD patients, enabling differentiation of 
DLB from AD [146]. FTLD rarely shows the same hypometabolic pattern as AD. In fact, 
differentiation of FTLD from AD can be done by assessment of frontal and anterior 
temporal hypometabolism, which is more prevalent and significant in FTLD than AD 
[147] . However, differentiation of FTLD from AD is better served using amyloid PET 
[148]. Vascular dementia (VaD) is another common dementia in older adults and can 
present with clinical symptoms similar to AD. In VaD, lower metabolism is often 
observed in the deep gray nuclei and cerebellum, which differentiates VaD from AD 
[149]. Clinically, the use of [18F]FDG PET in differentiating AD from non-AD dementias is 
important not only for accurate diagnosis, but to ensure the proper treatment. 
 
2.7 Summary 
 Without a doubt, it is clear that PET imaging has increased our understanding of 
the pathological and functional changes that occur in the living brain. The specific spatial 
and temporal patterns observed using [18F]FDG PET imaging enable clinicians and 
researchers to detect significant brain alterations in AD from prodromal and preclinical 
stages of the disease. Longitudinal PET studies suggest that glucose utilization begins 
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to decline before cognitive symptoms occur and continues to decline as disease 
progresses.  
PET, along with other neuroimaging techniques and biomarkers, will enable 
differential diagnosis among dementias and hopefully early and accurate detection and 
pre-mortem diagnosis of AD. Future studies that combine the longitudinal collection of 
multi-modal imaging and biomarker data will hopefully provide the information necessary 
for accurate pre-mortem diagnosis of AD.  
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Chapter 3: Glucose Metabolism in Multiple Systems Tauopathy with Presenile 
Dementia 
3.1 Introduction 
Frontotemporal dementia (FTD) is a clinically, genetically, and pathologically 
heterogeneous neurodegenerative disorder which is considered to be the second 
leading cause of early onset dementia after Alzheimer’s disease [150]. FTD is 
characterized by marked changes in behavior, personality, executive function, and 
language.  
Approximately 40-50% of patients with FTD report a positive family history of 
dementia, with 10% of these cases having an autosomal dominant inheritance pattern 
[151]. Up to 30% of familial FTD cases have been linked to genetic variations in the 
microtubule associated protein tau (MAPT) gene located at 17q21 [152]. These patients 
typically present with FTD with parkinsonism and with tau inclusions (FTDP-17T). 
Additional mutations in progranulin (PGRN), which is also located at 17q21, have been 
linked to familial FTD. However, histopathologically, mutations in PGRN are not 
associated with tau inclusions, while MAPT mutations are associated with tau pathology 
[153-155].  
A family with multiple systems tauopathy with presenile dementia (MSTD), a form 
of FTDP-17T, was discovered by our group to have an (a) to (g) transition in MAPT 
intron 10 +3 [9, 14, 156, 157]. In the normal adult human brain, six tau isoforms are 
expressed from the alternative splicing of MAPT exons 2, 3, and 10. The exclusion or 
inclusion of exon 10 leads to the expression of three (3R) or four (4R) repeat 
microtubule-binding domains, respectively, at a balanced ratio [16, 158]. The (a) to (g) 
transition in this family leads to an overproduction of the 4R tau isoform. Clinically, these 
patients have heterogeneous presentations, but present frequently as behavioral variant 
FTD (bvFTD) with changes in personality, such as disinhibition and disordered social 
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conduct, and impaired executive function, memory, and speech [159, 160]. Both clinical 
imaging and post-mortem assessment show marked neurodegeneration in medial 
temporal and frontal regions [161]. 
Previous studies have investigated grey matter (GM) loss and hypometabolism in 
sporadic bvFTD. Reduced glucose uptake has previously been identified in the frontal 
and temporal lobes, anterior cingulate cortex, anterior insula, and subcortical regions 
[162-169]. Additionally, [18F]fluorodeoxyglucose ([18F]FDG) positron emission 
tomography (PET) studies with other FTDP-17 families showed a reduction in glucose 
metabolism in temporal cortices, parietal cortices, hippocampi, and the amygdalae, 
although these samples were quite small [170-172]. Studies have also shown GM loss in 
the frontotemporal lobe regions, insula, and putamen [162, 171, 173, 174]. However, 
anatomical changes and glucose metabolism in the brain has yet to be reported in this 
MSTD family or in a FTDP-17 sample of this size.  
The goal of the present study is to investigate changes in glucose metabolism 
with [18F]FDG PET in MSTD to better define the metabolic features associated with 
MAPT mutations and further characterize this large MSTD family. Magnetic resonance 
imaging (MRI) was also utilized for comparison with [18F]FDG PET using an expanded 
sample from Spina et al. (2008) [161]. While the information derived from these two 
imaging modalities may identify abnormalities in the same structure that are related, 
there may be a temporal ordering of the onset of abnormalities detected by these 
complementary techniques. For example, glucose hypometabolism may precede grey 
matter atrophy as is observed in other familial neurodegenerative disorders [175]. We 
hypothesized that the MAPT intron 10 +3 mutation causes reduced glucose metabolism 
in carriers within this MSTD family, particularly in the medial temporal and frontal areas 
that are known to be susceptible to atrophy in bvFTD. We also hypothesized that 
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clinically-affected mutation carriers would show greater glucose hypometabolism in 
target areas than carriers who are not yet cognitively impaired.  
 
3.2 Material and Methods 
Subjects 
Nineteen participants, including eleven MAPT intron 10 +3 mutation carriers 
((eight symptomatic (SC), three asymptomatic (AC)) and eight non-carriers (NC), 
underwent neurological, and cognitive assessments, as well as [18F]FDG PET and 
structural magnetic resonance imaging (MRI) at the Indiana Alzheimer Disease Center 
(IADC). Demographic information for four of these SCs has previously been reported 
[161]. Participants were diagnosed with bvFTD using standard criteria [159, 176] from 
neuropsychological testing, neurological examination, informant interviews, and past 
medical records.  
 
Genotyping 
Genotyping of the MAPT intron 10 +3 mutation was performed as previously 
described [161]. Briefly, genomic DNA was extracted using standard protocols [161] and 
the purified DNA product from PCR amplification was compared to the known MAPT 
exon 10 sequence previously determined [9].   
 
Magnetic Resonance Imaging Acquisition and Processing 
All participants underwent a structural MRI scan within 1.00 ± 1.11 days (range: 
1-5 days) of the [18F]FDG PET scan. Seventeen participants, including ten MAPT intron 
10 +3 mutation carriers (7 symptomatic, 3 asymptomatic) and seven non-carriers, 
underwent a single T1-weighted SPGR volumetric scan on a 1.5T GE Signa scanner as 
previously described [161]. Two participants, one affected mutation carrier and one non-
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carrier, received a single T1-weighted MPRAGE volumetric scan on a 3T Siemens Trio 
scanner. Structural MRI scans were processed using voxel based morphometry (VBM) 
in SPM8 (http://www.fil.ion.ucl.ac.uk/spm/) using previously described techniques [177]. 
Briefly, scans were co-registered to a T1-weighted template and segmented into GM, 
white matter, and cerebrospinal fluid compartments using standard templates with bias 
correction. GM images were unmodulated, normalized to Montreal Neurologic Institute 
(MNI) space as 1 x 1 x 1 mm voxels, and smoothed with an 8mm full-width half 
maximum (FWHM) Gaussian kernel. All scans underwent extensive quality control at all 
processing steps. Only smoothed, normalized GM images generated from the SPGR 
volumes acquired on the 1.5T GE scanner were used in the VBM analysis, given the 
differences in data acquisition for 3T scans. Parameters generated from the structural 
MRI segmentation were also used for [18F]FDG PET processing as described below (see 
PET Data Acquisition and Imaging Processing).     
 
PET Data Acquisition and Image Processing 
All participants also underwent a [18F]FDG PET scan, acquired on a Siemens 
EXACT HR+ scanner. After positioning within the scanner, a 10-minute transmission 
scan using three internal rod sources was acquired for attenuation correction. A 60-min 
dynamic acquisition protocol was then initiated with the injection of approximately 10 
mCi of [18F]FDG using the following frame sequence: 12 x 5s, 4 x 15s, 2 x 30s, 7 x 60s, 
10 x 300s. [18F]FDG scans were reconstructed using the manufacturer’s software (CTI 
Molecular Imaging Inc.; Knoxville, TN) with the filtered back-projection algorithm. 
Corrections for scatter, randoms, and attenuation were applied. 
Reconstructed [18F]FDG scans were processed using standard techniques. 
Using SPM8, scans were converted from ECAT to NiFTI format, coregistered to the 
structural MRI scan from the same visit, motion corrected, and normalized to MNI space 
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using matrices from the same time-point MRI segmentation. A static [18F]FDG image 
from 30-60 minutes was created from the appropriate frames, intensity normalized using 
a cerebellar GM reference region to create a standardized uptake value ratio (SUVR) 
image for each participant, and smoothed with an 8 mm FWHM kernel. The SUVR 
images were then used for further analysis as described below.  
 
Image Analysis 
Within the SPM8 framework, an analysis of covariance (ANCOVA) was 
performed on normalized MRI GM density and [18F]FDG PET SUVR maps to compare 
the effect of mutation status (carrier vs. non-carrier) on GM density and [18F]FDG uptake 
on a voxel-by-voxel basis. Age at scan and sex were used as covariates for the 
[18F]FDG PET analysis. Age, sex, and total intracranial volume (tICV) were used as 
covariates for the GM density contrasts. In addition, since five of the NCs and two of the 
SCs were positive for apolipoprotein (APOE) ε4 allele, which has been shown to affect 
glucose metabolism in late mid-life [178], we computed similar analyses for both 
[18F]FDG and GM density that also included APOE ε4 carrier status as covariate. 
However, the inclusion of APOE ε4 carrier status did not significantly affect the observed 
results and thus was not included in the final reported results (data not shown). An 
explicit GM mask was applied to both MRI and PET datasets to restrict the search area. 
Significant findings were displayed using a threshold of p<0.001 (uncorrected) for MRI, 
and a threshold of p<0.01 (uncorrected) for [18F]FDG PET; for both analyses, minimum 
cluster size was (k) = 50 voxels. A composite image using the significant clusters for MRI 
and [18F]FDG PET was created to determine areas of MRI and PET overlap between 
mutation carriers and non-carriers. MarsBaR toolbox (version 0.42) in SPM was used to 
extract mean GM density and mean glucose uptake for the significant medial temporal 
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lobe (MTL) clusters from MRI and PET analyses, respectively. Note that MRI results for 
four MAPT 10 +3 mutation carriers has been previously reported [161]. 
 
Statistical Analysis 
While the three diagnostic groups were too small to do voxel-based imaging 
analysis, we had a special interest in the AC group and wanted to determine if they 
showed any regional metabolic, GM density, and/or neuropsychological differences from 
NC and SC participants. An ANCOVA was used to test for the association of continuous 
demographic variables and neuropsychological test performance with mutation and 
diagnostic status. Sex was assessed with mutation and diagnostic status using a chi-
square test. Age and years of education were used as covariates when evaluating 
neuropsychological test scores. Z-scores of left and right mean MTL GM density and 
MTL glucose uptake from the significant MTL clusters identified in previous voxel-wise 
analyses were calculated for each participant using means and standard deviations from 
the NC group. The left and right z-scores were then averaged to create a bilateral mean 
GM density and bilateral mean glucose uptake z-score for each participant. ANCOVA 
was again used to test the association of diagnostic/mutation group (SC, AC, NC) with 
MTL GM density and glucose uptake z-scores. Age and sex were used as covariates for 
the assessment of MTL glucose uptake, while age, sex, and tICV were used as 
covariates for the evaluation of MTL GM density. Pairwise contrasts between groups 
were adjusted for multiple comparisons using a Bonferroni correction. Linear regression 
was used to compare MTL GM density and MTL glucose uptake. All statistical analyses 
were done in SPSS (version 20.0, Chicago, IL) and all graphs were created using 
SigmaPlot (version10.0). 
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3.3 Results 
Neuropsychological assessment 
Demographics and neuropsychological testing results are displayed in Table 1.  
Although not statistically significant, symptomatic carriers were on average older and 
more likely to be male than the other groups. Thus, age and sex were used as 
covariates in all subsequent neuroimaging analyses. As expected, a significant 
association between diagnostic/mutation status group and neuropsychological 
performance was observed on the COWA (p=0.045) and the CERAD Word List 
Immediate Recall (p=0.006) and Delayed Recall (p<0.001). Upon post-hoc analysis, SCs 
showed poorer performance on the COWA than NCs (p=0.044). In addition, ACs and 
NCs showed better performance than SCs on the CERAD Word List Immediate Recall 
(SC vs. AC, p=0.022; SC vs. NC, p=0.012) and Delayed Recall (SC vs. AC, p=0.004; SC 
vs. NC, p<0.001). 
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Table 1. Demographic and neuropsychological data in MSTD participants.  
 SC AC NC  p-value 
N 8 3 8   
Age (years) 50.1 (5.4) 42.55 (8.7) 43.7 (12.0)  0.313 
Sex (M, F) 5, 3 0, 3 2, 6  0.106 
Education (years) 12.75 (0.9) 14.3 (2.1) 13.4 (1.3)  0.764 
% APOE ε4+ 25 0 62.5  0.106 
MMSE Total Score 23.6 (5.6) 28.3 (0.6) 27 (1.6)  0.189 
COWA Total Score* 22.1 (10.6) 33.7 (6.7) 38.86 (10)  0.045 
Block Design Total* 23.4 (12.8) 33.3 (10) 34.43 (4.2)  0.235 
Word List Imm Total** 11.75 (5.5) 28 (1.4) 21.9 (4.6)  0.006 
Word List Del Total** 2.75 (2) 9.5 (0.7) 8.13 (1.6)  <0.001 
 
SC = symptomatic carrier; AC = asymptomatic carrier; NC = non-carrier; M = male; F = 
female; MMSE = Mini-Mental State Exam; COWA = Controlled Oral Word Association; 
Word list Imm = CERAD Word List – Immediate Recall; Word List Del = CERAD Word 
List – Delayed Recall. Mean (Standard Deviation). * Missing one non-carrier. ** Missing 
one asymptomatic carrier.  
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MRI 
Cerebral atrophy was observed in MAPT mutation carriers relative to non-
carriers. Specifically, decreased GM density was observed bilaterally in the MTL, 
including in the parahippocampal gyri, hippocampi, entorhinal cortices, uncus, and 
amygdala, as well as in the caudate nucleus (Figure 2; voxel-wise threshold of 
p<0.001(uncorrected for multiple comparisons); k = 50 voxels)). GM atrophy was also 
observed in mutation carriers in the precuneus, insula, medial and superior frontal gyri, 
and the precentral gyrus, in addition to other regions of the frontal, parietal, occipital, and 
lateral temporal lobes (Figure 2). However, as has been seen in previous bvFTD studies, 
there were surprisingly few differences between mutation carriers and non-carriers in the 
prefrontal cortex and cingulate gyrus.  
The most striking GM atrophy in mutation carriers was seen bilaterally in the MTL 
(Figure 2), as has been previously shown [161]. Further analysis of these regions to 
evaluate distribution of atrophy among diagnostic/mutation groups showed a significant 
overall difference in GM density z-score (Figure 3, p<0.001). Pairwise comparisons 
showed reduced GM density in both AC and SC relative to NC (NC vs. AC, p=0.022; NC 
vs. SC, p<0.001). GM atrophy in AC was intermediate between that of NC and SC, with 
significantly more atrophy than NC but less atrophy than SC (AC vs SC, p=0.01). 
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Figure 2. Voxel-wise analysis of the effect of MAPT intron 10 +3 mutation status on 
GM density.  
Whole-brain grey matter (GM) density was compared between carriers of the 
MAPT intron 10 +3 mutation and non-carriers. Mutation carriers show GM atrophy 
relative to non-carriers in regions of the (A) medial temporal lobe and, (B) other cortical 
and subcortical regions. Differences between mutation carriers and non-carriers are 
displayed at a voxel-wise threshold of p<0.001 (uncorrected for multiple comparisons) 
and minimum cluster size (k) = 50 voxels. Age, sex, and total intracranial volume were 
used as covariates.  
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Figure 3. Medial temporal lobe GM density and glucose metabolism in carriers and 
non-carriers of the MAPT intron 10 +3 mutation.  
Mean grey matter (GM) density and glucose metabolism were extracted from the 
medial temporal lobe (MTL) clusters identified in the voxel-wise comparisons (Figures 2 
and 4) using MarsBaR. Z-scores were then calculated and the effect of mutation and 
clinical status on GM atrophy and glucose hypometabolism was evaluated, covaried for 
age and sex. Total intracranial volume was also included in the analysis of GM atrophy. 
Significant differences between groups were observed for both GM density (p<0.001) 
and glucose uptake (p<0.001). Post-hoc comparisons of GM density showed a 
significant difference between all group pairs, with symptomatic carriers (SC) showing 
the greatest MTL atrophy and asymptomatic carriers showing intermediate MTL atrophy 
between SC and mutation non-carriers (NC; NC vs. AC, p=0.022; NC vs. SC, p<0.001; 
AC vs SC, p=0.01). Post-hoc comparisons of glucose uptake demonstrated significant 
greater glucose metabolism in NC relative to both carrier groups (NC vs. AC (p=0.004) 
and NC vs. SC (p<0.001)), but no difference between carriers based on clinical status 
(p=0.154). 
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[18F]FDG PET 
Bilateral hypometabolism was observed in mutation carriers relative to non-
carriers in regions of the MTL and limbic system, including the parahippocampal gyri, 
hippocampi, entorhinal cortices, amygdala, uncus, and the anterior cingulate cortex, as 
well as in the caudate nucleus (Figure 4, Table 2). Some lateralization of 
hypometabolism in mutation carriers relative to non-carriers was observed with more 
reductions in glucose metabolism in the right anterolateral temporal lobe than in the left. 
Other frontal and parietal cortical regions also showed hypometabolism in mutation 
carriers relative to non-carriers, including in the anterior prefrontal cortex, the medial and 
superior frontal gyri, and the postcentral gyrus (Figure 4).   
  Further examination of the difference in glucose metabolism among the three 
groups in the MTL showed a significant association of diagnostic/mutation status with 
mean MTL glucose SUVR z-score (Figure 3; p<0.001). The asymptomatic carriers again 
showed mean MTL glucose uptake intermediate between the NC and SC. Comparisons 
of NC and AC (p=0.004) and NC and SC (p<0.001) reached statistical significance, 
whereas the AC and SC carrier groups (p=0.154) were not significantly different.  
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Table 2. Anatomical distribution of reduced glucose metabolism for in MAPT 
intron 10 +3 carriers relative to non-carriers. 
   
MNI Coordinates 
 
Location BA T-value x y z p-value 
L. Inferior Frontal Gyrus 47 4.58 −26 10 −18 0.000 
L. Inferior Parietal Lobule 40 3.11 −58 −32 46 0.004 
L. Middle Frontal Gyrus 10 3.38 −26 66 12 0.002 
6 2.92 −46 10 50 0.005 
9 3.03 −52 26 34 0.004 
L. Middle Temporal Gyrus 21 3.29 −56 2 −18 0.002 
2.98 −64 −10 −12 0.005 
2.68 −58 −18 −6 0.009 
L. Superior Frontal Gyrus 10 2.83 −36 48 32 0.006 
6 3.55 −20 6 70 0.001 
3 −8 28 66 0.004 
8 3.96 −6 44 52 0.001 
3.13 −22 32 56 0.003 
L. Superior Parietal Lobule 7 3.34 −28 −58 64 0.002 
L. Superior Temporal Gyrus 10 4.77 −14 70 18 0.000 
38 3.85 −22 14 −34 0.001 
L. Thalamus   3.22 −8 −32 −4 0.003 
L. Uncus 34 4.42 −18 2 −22 0.000 
R. Anterior Cingulate 32 3.71 2 46 6 0.001 
R. Caudate Body   3.98 16 22 16 0.001 
  3.57 14 12 20 0.001 
R. Medial Frontal Gyrus 25 5.29 8 6 −22 0.000 
R. Middle Frontal Gyrus 8 3.1 40 24 56 0.004 
R. Middle Temporal Gyrus 21 3.92 64 −6 −12 0.001 
R. Postcentral Gyrus 7 3.16 16 −52 72 0.003 
R. Superior Frontal Gyrus 10 4.66 22 68 14 0.000 
4.1 16 62 28 0.000 
6 3.11 14 32 60 0.004 
8 2.94 20 38 52 0.005 
R. Superior Parietal Lobule 7 3.47 18 −68 58 0.002 
R. Superior Temporal Gyrus* 38 5.99 44 16 −22 0.000 
R. Uncus 34 4.57 20 4 −22 0.000 
MNI = Montreal Neurologic Institute; BA = Brodmann area; L.= left; R.= right 
p-value <0.01, uncorrected 
*Significant cluster for p<0.05 at FWE-corrected  
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Figure 4. Voxel-wise analysis of the effect of MAPT intron 10 +3 mutation status on 
glucose metabolism.  
Whole-brain glucose metabolism was compared between carriers of the MAPT 
intron 10 +3 mutation and non-carriers. Mutation carriers showed hypometabolism 
relative to non-carriers in the (A) medial temporal lobe (MTL), (B) caudate nucleus, (C) 
anterior cingulate gyrus, and (D) in frontal, parietal, and temporal cortices. Group 
differences are displayed at a voxel-wise threshold of p<0.01 (uncorrected for multiple 
comparisons) and minimum cluster size (k) = 50 voxels. Age and sex were used as 
covariates.   
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Comparison of MRI and [18F]FDG 
In other familial neurodegenerative disorders (i.e. familial Alzheimer’s disease), 
hypometabolism may precede brain atrophy [175]. Therefore, we investigated the 
relationship between MRI and PET findings in the MSTD sample. There was moderate 
overlap of the regions showing neurodegeneration and those showing glucose 
hypometabolism in mutation carriers relative to non-carriers, most especially in the MTL 
(Figure 5). While significant overlap can be seen in MTL structures such as the uncus, 
hippocampus, and parahippocampal gyrus, atrophy appeared to be more widespread 
than hypometabolism in mutation carriers relative to non-carriers. However, other 
regions, including the anterior cingulate cortex and caudate nucleus, showed very little 
or no overlap of GM atrophy and reduced glucose metabolism. When left and right MTL 
atrophy and glucose metabolism measures were directly compared, reduced GM density 
was highly associated with reduced glucose hypometabolism (left: r=0.93, p<0.001; 
right: r=0.88, p<0.001; Figure 6).  
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Figure 5. Anatomical overlap of GM atrophy and glucose hypometabolism in 
MAPT intron 10 +3 mutation carriers relative to non-carriers.  
The overlap of regions showing significantly reduced GM density (red) and 
[18F]FDG uptake (blue) for MAPT intron 10 +3 carriers relative to non-carriers is 
presented. Significant overlap is observed in the medial temporal lobe (MTL) and other 
temporal regions, while little overlap is seen in cortical and striatal regions. Images 
shown here are displayed at a voxel-wise threshold of p<0.001 (uncorrected for multiple 
comparisons) for GM density and p<0.01 (uncorrected for multiple comparisons) for 
glucose uptake, both with minimum cluster size (k) = 50 voxels. The GM density 
comparison was covaried for age, sex, and total intracranial volume, while the [18F]FDG 
PET analysis was covaried for age and sex. 
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Figure 6. Relationship between medial temporal lobe atrophy and hypometabolism 
in carriers and non-carriers of the MAPT intron 10 +3 mutation.  
A significant association between grey matter (GM) density and glucose 
metabolism in the left and right medial temporal lobe (MTL) was observed across and 
within groups. Individual data points represent raw GM density and [18F]FDG SUVR 
values. The reported R-squared value corresponds to the correlation across all 
participants, covaried for age, sex, and total intracranial volume. Linear fits are shown for 
individual groups, including non-carriers (dotted line), asymptomatic carriers (dashed 
line), and symptomatic carriers (solid line). 
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3.4 Discussion 
Although MRI and [18F]FDG PET studies have been reported for sporadic bvFTD 
[162-167, 170], few studies have investigated changes in glucose metabolism or brain 
atrophy in FTDP-17T [170, 179]. Our findings show that individuals with the MAPT 
mutation at position +3 of intron 10 have prominent GM atrophy bilaterally in the MTL 
regions and reduced glucose metabolism in MTL regions and the prefrontal cortex, when 
compared to non-carriers. Furthermore, asymptomatic mutation carriers showed 
anatomical and metabolic changes intermediate between the SC and NC participants.  
We also observed substantial overlap in cortical atrophy and hypometabolism, 
specifically in MTL regions.  
 
MRI Findings 
VBM results for four of the eleven MSTD patients used in this study have been 
previously reported, and showed extensive GM loss in the hippocampus, 
parahippocampal gyrus, insular cortex, and to a lesser extent, the anterior cingulate 
cortex, head of the caudate nucleus, posterolateral orbital cortex, and insular cortex 
[161]. Results in the expanded sample are similar to the previous findings by Spina et al. 
with increased statistical power [161]. The prominent atrophy in mutation carriers 
compared to non-carriers in the MTL is similar to findings from studies of other familial 
FTD with MAPT mutations [171, 173, 174, 179-181]. However, contrary to other bvFTD 
studies, our results showed very little GM atrophy in the frontal lobes [182]. The MSTD 
patients did show anterior temporal atrophy, which is consistent with the new diagnostic 
criteria for bvFTD [160]. The AC group showed a level of atrophy intermediate between 
the NC and SC groups, with significant differences detected between all groups. This 
suggests that neurodegeneration occurs prior to clinical decline in mutation carriers, 
perhaps years before expected clinically significant decline. However, it is of importance 
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to note that the sample size of the AC group prohibited voxel-based analysis, thus 
further studies should be done to increase the power of this analysis.  
 
[18F]FDG PET Metabolism 
Prior bvFTD studies have demonstrated hypometabolism in frontal and temporal 
lobes, anterior cingulate cortex, anterior insula, and subcortical regions [162-169]. MSTD 
mutation carriers showed near symmetrical hypometabolism in the MTL, parietal cortex, 
and frontal cortex relative to non-carriers. Consistent with the diagnosis for probable 
bvFTD [160], anterior temporal hypometabolism was observed, affecting the right 
hemisphere more than the left. Several subcortical structures, many of which belong to 
the limbic system known to regulate emotion and memory, showed glucose 
hypometabolism in the MAPT intron 10 +3 mutation carriers when compared to non-
carriers, consistent with the clinical presentation of these participants. These regions 
include the cingulate gyrus, uncus, parahippocampal gyri, entorhinal cortex, and 
amygdala. The most notable reduction in glucose uptake was seen in the MTL, which is 
similar to other studies in FTDP-17T [170, 171]. Interestingly, glucose uptake in the AC 
group was between that of the NC and SC groups, suggesting a reduction in glucose 
metabolism prior to clinical decline. Utility of this [18F]FDG PET predictor biomarker will 
require future longitudinal follow-up studies. No significant difference in glucose 
metabolism was observed between AC and SC, which may be a function of the small 
size of the AC group or may suggest the majority of the metabolic decline occurs prior to 
significant clinical symptomatology. Larger samples and longitudinal follow-up should be 
completed to help resolve this issue. 
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Comparison of Cortical Atrophy and Glucose Metabolism 
Cortical atrophy and hypometabolism in the MTL were strongly associated in the 
present study. The distribution of metabolic changes also overlaps previously described 
patterns of neurodegeneration in MSTD patients and are consistent with the clinical 
characteristics of their cognitive dysfunction [161]. The striking similarity between the 
MRI and [18F]FDG PET results and the high correlation of mean GM density and 
[18F]FDG uptake in this region also raises a question as to whether the observed 
hypometabolism is due to a reduction in local GM tissue in the MTL. However, given the 
marked effect of the MSTD mutation, it seems likely that the functional hypometabolism 
and structural neurodegenerative changes are occurring concurrently in these patients 
as two aspects of the underlying disease process. Both MTL glucose uptake and cortical 
atrophy in the AC group were intermediate between the NC and SC groups. The 
differences in cortical atrophy were significant between all groups, whereas the AC and 
SC participants were not significantly different in glucose uptake. In other words, the 
hypometabolism in ACs before onset of clinical symptomatology is similar to SC, while 
the change in MTL atrophy is intermediate. These results suggest the possibility that 
hypometabolism may occur before atrophic changes are detectable, which would 
support the hypothesis that the change in metabolism is not of direct consequence of 
atrophy, as ambiguous similar findings have been observed in a previous study of 
Alzheimer’s disease [183]. The lack of observable atrophy in hypometabolic regions in 
the anterior cingulate cortex and caudate nucleus also support the hypothesis that 
dysfunctional glucose metabolism may predate atrophy in disease-associated regions. 
However, these differences between cortical atrophy and glucose metabolism, or lack 
thereof, could also be due to different variability in the [18F]FDG PET and structural MRI 
measures, which complicates interpretation.  
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Study Limitations 
As previously indicated, the present study contains limitations. First, the AC 
group was small, which permitted quantitative ROI analysis but not voxel-based mapping 
of differences between the three groups. Further studies with a larger samples would 
provide the power needed to better detect the structural and metabolic differences in 
asymptomatic mutation carriers and would offer a better assessment of the impact of 
mutation status and clinical symptoms on the relative rates of cortical atrophy and 
cognitive dysfunction. Additionally, it is possible that the hypometabolism observed by 
the mutation-positive group was an effect of the cortical atrophy, as quantitative analysis 
of the MTL also showed the two variables (metabolism, atrophy) were highly correlated. 
While mutation status appeared to be causal for both the lower GM density and glucose 
uptake, once again, the small sample size of the AC group prevented us from having the 
power to fully determine the topography of differences across groups. Prospective 
longitudinal studies will be important in order to investigate the temporal relationships 
between metabolic and structural neuroimaging changes. Other functional imaging 
modalities could also prove informative with regard to early changes in brain networks, 
activation dynamics, and regional cerebral blood flow. Future studies with recently 
developed tau-specific PET tracers are also likely to elucidate the pattern of early 
changes and may provide better prediction of neurodegeneration and cognitive decline 
[184, 185]. Overall, these results suggest that neuroimaging, in addition to genetic 
testing, may provide useful insights into the sequence of disease processes and 
characterization of the effects of MAPT mutation, especially in the prodromal stage of 
MSTD.  
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Summary 
Cortical atrophy and hypometabolism were observed in MSTD patients, 
especially in the MTL. These changes in brain structure and function are consistent with 
the observed cognitive dysfunction in these patients. Furthermore, reduced glucose 
metabolism and atrophy in the MTL were observed in asymptomatic carriers, suggesting 
these changes precede clinical onset. Future studies of expanded samples with 
longitudinal follow-up are needed to replicate the observed results and further elucidate 
the role of structural and functional brain changes in patients with MSTD.   
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Chapter 4: PET Signatures in Gerstmann–Sträussler–Scheinker Disease  
4.1 Introduction 
Gerstmann–Sträussler–Scheinker (GSS) disease is an autosomal-dominant 
neurodegenerative disorder associated with prion protein (PrP) gene (PRNP) mutations 
[186-188]. Onset occurs most frequently between the fourth and the sixth decades of 
life, with an average disease duration of five years. GSS is clinically characterized by 
ataxia, extrapyramidal signs, and cognitive impairment [189, 190]. The neuropathologic 
diagnosis is based on the presence of unicentric and multicentric APrP plaques in the 
cerebrum and cerebellum; however, the distribution and severity of PrP deposits vary 
substantially among GSS phenotypes [191]. A point mutation in PRNP at codon 198 
(c.593T>C) results in a form of GSS (p.Phe198Ser; F198S) that is neuropathologically 
characterized by neurofibrillary tangles with paired helical filaments, in addition to PrP 
amyloid deposition [75, 188, 192, 193]. Patients with valine (V) homozygosity at codon 
129 have an onset of disease more than 10 years earlier than those who are 
heterozygous for methionine (M)/V at codon 129 [192]. 
Previous [18F]Fluorodeoxyglucose (FDG) positron emission tomography (PET) 
studies measuring glucose metabolism in GSS are extremely limited and likely to show 
varying results due to phenotypic heterogeneity of the different PRNP mutations [194-
197]. Two symptomatic GSS F198S subjects have been previously been examined with 
[18F]FDG PET. Results of this study suggest reduced [18F]FDG uptake in the striatum, 
thalamus, and frontal and parietal cortices, as well as the cerebellum, without 
involvement in the medial temporal lobe [196]. However, studies have yet to examine 
glucose metabolism in a GSS family of a relatively large size. 
Additionally, in vivo imaging of amyloid has become a valuable tool for evaluating 
amyloid plaque burden. [11C]Pittsburgh compound B (PiB) is a PET radioligand with a 
high affinity for beta-amyloid (Aβ) fibrils [115]. [11C]PiB retention is strongly correlated 
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with the presence of amyloid deposits made of Aβ protein in the post-mortem brain of 
patients with Alzheimer’s disease. [11C]PiB binds with high affinity to the β-sheet 
structure of Aβ plaques and fails to show retention with other abnormally conformed 
proteins such as tau of neurofibrillary tangles and α-synuclein of Lewy bodies [114, 115]. 
However, one case study showed cerebellar [11C]PiB retention in a subject with BRI-
amyloid (ABri) deposition, suggesting that [11C]PiB may be capable of binding non-Aβ 
proteins found in plaques [198].  
Like Aβ and ABri, APrP contains a higher-order β-sheet secondary structure. 
Neuropathological dyes such as the Congo Red derivative (trans, trans),-1-bromo-2,5-
bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB) and the Thioflavin T derivative 
[4′-(methylamino)phenyl] benzothiazole (BTA-1) bind these three types of amyloid, both 
in vitro and in vivo in mouse and human brains [199, 200]. Given that [11C]PiB is a 
Thioflavin T derivative, we hypothesized that it may also bind to other amyloid proteins in 
addition to Aβ and ABri. Previous [11C]PiB PET studies have demonstrated that [11C]PiB 
is not specifically retained in individuals affected by a prion disease; however, the 
majority of these reports were based on single case studies and a heterogeneous 
sample of prion diseases [197, 201-204].  
 The purpose of this study was to evaluate (1) if [11C]PiB PET is capable of 
detecting APrP in PRNP P102L (proline to leucine at codon 102) or F198S 
(phenylalanine to serine at codon 198) gene carriers, and (2) assess brain glucose 
metabolism using [18F]FDG PET on a voxel-wise basis in GSS F198S mutation carriers. 
For the [11C]PiB PET study, we evaluated cross-sectional and longitudinal [11C]PiB PET 
scans in asymptomatic carriers of either the PRNP P102L or the PRNP F198S point 
mutations, relative to non-carriers. Furthermore, in a symptomatic GSS F198S patient, 
we investigated the neuropathologic changes and correlated these findings with the 
[11C]PiB PET data that was obtained 46 months prior to death. Determining the ability of 
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[11C]PiB PET to detect APrP would provide evidence about the suitability of this tracer in 
trials of novel therapeutics or in early detection of PrP amyloidosis and differentiating 
them from other prion disease.    
To our knowledge, this is the largest study to investigate [18F]FDG uptake in GSS 
subjects with the F198S mutation. Additionally, this is the first study to investigate the 
sensitivity of [11C]PiB PET for binding APrP plaques in the P102L and F198S GSS 
mutation.  
 
4.2 Materials and Methods 
Participants 
A total of 25 participants with, or at risk for GSS were included in this study. 
Investigators were initially blinded to the participant’s genetic status related to the PRNP 
gene. Investigators were later unblinded after obtaining all neuropsychological and 
imaging data reported in the present paper. Neuropsychological testing, cognitive 
assessments, and neuroimaging was completed at the Indiana Alzheimer Disease 
Center (IADC). In addition, neuropsychological, clinical, and [11C]PiB PET data from 
eight cognitively healthy non-carriers (NC) from a separate study on aging and dementia 
at the IADC (the Indiana Memory and Aging Study (IMAS) were included for the amyloid 
study. All NC and asymptomatic carriers (AC) displayed no clinically relevant cognitive 
impairment or significant cognitive complaints. All participants or their legally authorized 
representative provided written informed consent according to the Declaration of Helsinki 
and all procedures were approved by the Indiana University Institutional Review Board. 
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Genotyping  
Identification of point mutations in the PRNP gene was done as previously 
described [188]. Briefly, genomic DNA was isolated from fresh blood. The complete 
PRNP gene was amplified and direct sequencing performed using the DTCS quick start 
kit (Beckman Coulter, Fullerton, CA). The products were loaded onto a CEQ 8000 GeXP 
Genetic Analysis System (Beckman Coulter). DNA sequences were compared with the 
published PRNP sequence (www.ncib.nlm.nih.gov). 
 
Acquisition and Processing of Magnetic Resonance Imaging Data (baseline only) 
All participants underwent a structural MRI scan on the same day of the [18F]FDG 
PET scan except for three NCs (range: 1-12 days). Fifteen participants, including nine 
GSS-F198S mutation carriers (5 symptomatic, 4 asymptomatic) and six NCs, underwent 
a single T1-weighted SPGR volumetric scan on a 1.5T GE Signa scanner as previously 
described [161]. Seven participants (2 SCs, 1 AC, and 4 NCs) received a single T1-
weighted MPRAGE volumetric scan on a 3T Siemens Trio scanner. Structural MRI 
scans were processed using voxel based morphometry (VBM) in SPM8 
(http://www.fil.ion.ucl.ac.uk/spm/) using previously described techniques [177]. Briefly, 
scans were co-registered to a T1-weighted template and segmented into grey matter 
(GM), white matter (WM), and cerebrospinal fluid (CSF) compartments using standard 
templates with bias correction. GM images were unmodulated, normalized to Montreal 
Neurologic Institute (MNI) space as 1 x 1 x 1 mm voxels, and smoothed with an 8mm 
full-width half maximum (FWHM) Gaussian kernel. All scans underwent extensive quality 
control at all processing steps. Only smoothed, normalized GM images generated from 
the SPGR volumes acquired on the 1.5T GE scanner were used in the VBM analysis, 
given the differences in data acquisition for 3T scans. Parameters generated from the 
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structural MRI segmentation were also used for [18F]FDG PET processing as described 
below (see Acquisition and Processing of [18F]FDG PET Data below).     
Acquisition and Processing of [18F]FDG PET Data  
Twenty-two participants also underwent a [18F]FDG PET scan, acquired on a 
Siemens EXACT HR+ scanner. After positioning within the scanner, a 10-minute 
transmission scan using three internal rod sources was acquired for attenuation 
correction. A 60-min dynamic acquisition protocol was then initiated with the injection of 
approximately 10 mCi of [18F]FDG using the following frame sequence: 12 x 5s, 4 x 15s, 
2 x 30s, 7 x 60s, 10 x 300s. [18F]FDG scans were reconstructed using the 
manufacturer’s software (CTI Molecular Imaging Inc.; Knoxville, TN) with the filtered 
back-projection algorithm. Corrections for scatter, randoms, and attenuation were 
applied. 
Reconstructed [18F]FDG scans were processed using standard techniques. 
Using SPM8, scans were converted from ECAT to NiFTI format, coregistered to the 
structural MRI scan from the same visit, motion corrected, and normalized to MNI space 
using matrices from the same time-point MRI segmentation. A static [18F]FDG image 
from 30-60 minutes was created from the appropriate frames, intensity normalized using 
a pons reference region to create a standardized uptake value ratio (SUVR) image for 
each participant, and smoothed with an 8 mm FWHM kernel. The SUVR images were 
then used for further analysis as described below (see Image Analysis below).  
 
Acquisition and Processing of [11C]PiB PET Data 
Fourteen PRNP P102L and F198S participants (9 NC, 4 AC, 1 SC) received a 
baseline [11C]PiB PET scan, acquired on a Siemens EXACT HR+ scanner. Three 
asymptomatic carriers (2 PRNP P102L, 1 PRNP F198S) also received a second [11C]PiB 
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PET scan approximately one year after the initial scan. Prior to each scan, a 10-minute 
transmission scan using three internal rod sources was acquired for attenuation 
correction. For the six individuals at risk for GSS (1 NC, 4 AC, 1 SC) injection of [11C]PiB 
was followed by a 40min uptake period. Dynamic data acquisition protocol was then 
initiated with the following frame sequence: 6 x 5min. Two participants from the IMAS 
study received a similar protocol as those at risk for GSS (40min uptake period, dynamic 
acquisition, frame sequence: 10 x 5min). In the other 6 participants from IMAS (6 NC), 
data acquisition was initiated with the injection of [11C]PiB and the frame sequence was: 
10 x 30sec, 9 x 1min, 2 x 3min, 8 x 5min, 3 x 10min. The average [11C]PiB injected 
across all participants (those at risk for GSS and IMAS) was 11.17±2.0 mCi. Scans were 
reconstructed using manufacturer’s software (Siemens; Knoxville, TN) for filtered back-
projection. Corrections for scatter, randoms, and attenuation were applied. 
Reconstructed [11C]PiB scans were processed using standard techniques. Using 
Statistical Parametric Mapping 8 (SPM8; Welcome Department of Cognitive 
Neuroscience, London, UK), scans were converted from ECAT to NiFTI format, 
coregistered to the structural MR) scan from the same visit (3T MPRAGE scan; Siemens 
Tim Trio), spatially aligned on a frame-by-frame basis, and normalized to MNI space 
using matrices from segmentation of the same time-point MRI. A static [11C]PiB image 
from 40-70 minutes was created from the appropriate frames (depending on scan 
acquisition type (see above)) and was intensity normalized using a pons reference 
region to create a SUVR image for each participant. SUVR images were smoothed with 
an 8 mm FWHM Gaussian kernel.  
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Image Analysis 
Using SPM8, an ANCOVA was performed on normalized MRI GM density (1.5T 
only) and [18F]FDG PET SUVR images (all subjects) to compare the effect of diagnostic 
status (NC vs. AC vs. SC) on GM density and FDG uptake on a voxel-by-voxel basis. 
Age at time of scan, sex, and total intracranial volume (tICV) were used as covariates for 
the MRI analysis. Age at time of scan and sex were used as covariates for the [18F]FDG 
PET analysis. In addition, since the M/V codon 129 status is known to influence the 
clinical and pathological phenotypes of the GSS F198S mutation, separate MRI and 
[18F]FDG PET analyses were also computed using codon 129 status as an additional 
covariate. An explicit GM mask was applied to both MRI and PET analyses to restrict the 
search area for statistical analysis. Significant findings were displayed using a threshold 
of p<0.001 (uncorrected) for MRI and a threshold of p<0.01 (uncorrected) for [18F]FDG 
PET; for both analyses, minimum cluster size (k) was 50 voxels. A composite image 
using the significant clusters for MRI and [18F]FDG PET was created to qualitatively 
investigate areas of overlap of diagnostic differences in the MRI and PET analyses. The 
MarsBaR toolbox (version 0.42) in SPM was used to extract mean GM density and 
mean glucose uptake for the significant clusters from MRI and PET analyses, 
respectively. 
Visualization of the average group [11C]PiB images served as a primary 
qualitative assessment. Mean baseline [11C]PiB SUVR images and mean normalized 
baseline structural MR images for each diagnostic/mutation status group were created 
using SPM8. To visualize [11C]PiB retention by group, mean [11C]PiB SUVR images was 
overlaid onto the respective group mean MR images in MRIcron 
(http://www.mccauslandcenter.sc.edu/mricro/mricron/). For each participant, mean 
[11C]PiB SUVR values were extracted from a global cortical GM region of interest (ROI) 
and a whole cerebellum ROI defined from the AAL atlas and extracted using MarsBaR 
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[205]. SUVR values from each ROI were compared between diagnostic/mutation status 
groups as described below (Statistical Analysis). In the three AC subjects with follow-up 
scans, the extracted mean [11C]PiB SUVR values from the ROIs at both time-points were 
graphed to complement qualitative visual observations. 
 
Statistical Analysis 
A chi-square test was used to assess the differences in sex and PRNP-129M/V 
status by diagnosis/mutation group. Continuous demographic variables and baseline 
neuropsychological test performance were evaluated using an ANCOVA model to 
examine the differences between NC and mutation carriers. Age and years of education 
were used as covariates when evaluating neuropsychological test scores. An ANCOVA 
model was also used to test for association of mutation status (carrier vs. non-carrier) 
with mean [11C]PiB or mean [18F]FDG SUVR values from the global cortical GM and 
cerebellar ROIs, covaried for age and sex. Although the small sample number precluded 
statistical analysis, the mean [18F]FDG SUVR values from the significant regions from 
identified in the comparison of glucose metabolism in NCs relative to SCs (NCs>SCs), 
and PRNP-129M/V status were graphed. The relationship between mean [18F]FDG 
SUVR and mean GM density from the significant regions from identified in the 
comparison of glucose metabolism in NCs relative to SCs (NCs>SCs) and memory and 
motor function was assessed using a partial Pearson correlation using age, sex, and 
tICV as covariates. For the Groove Pegboard Test, number of peg drops was added as 
an additional covariate. Z-scores for GMD and SUVR from significant regions of interest 
identified in the previous analysis were calculated for each participants using means and 
standard deviations from the NC group. A linear regression was used to determine the 
relationship between GMD and SUVR. Age, sex, and tICV were used as covariates. 
Bonferroni correction was used to adjust for multiple comparisons between groups. All 
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statistical analyses employed SPSS (version 24.0, Chicago, IL) and graphs were created 
with SigmaPlot (version 10.0). 
 
Neuropathologic Assessment 
 The symptomatic individual (PRNP F198S) expired 46 months after the [11C]PiB 
scan. Tissue was harvested at Indiana University School of Medicine. The fresh brain 
was hemisected along the mid-sagittal plane. The left hemibrain was fixed in formalin 
and the right hemibrain was sliced, frozen, and stored at −70 °C.  
 Following fixation in a 10 % formalin solution, brain tissue samples were 
dehydrated in graded alcohols, cleared in xylene, and embedded in paraffin. Eight-
micrometer-thick sections from multiple brain areas were stained with the histological 
and immunohistochemical methods described below. Hematoxylin and eosin (H&E) and 
luxol fast blue with hematoxylin & eosin (LFB-H&E) were used to survey gray and white 
matter for neuronal losses, gliosis, vascular pathology, and other possible pathologic 
lesions. Thioflavin S method was used to visualize amyloid deposits and neurofibrillary 
tangles.  Neurodegenerative pathology was analyzed using antibodies raised against 
amyloid β (Aβ) (21F12), tau (AT8), and prion protein (PrP; 3F4).    
 The signal from polyclonal antibodies was visualized using avidin–biotin, with 
goat anti-rabbit immunoglobulin as the secondary antibody, followed by horseradish 
peroxidase-conjugated streptavidin and the chromogens diaminobenzidine or 
tetramethylbenzidine. The signal from monoclonal antibodies was detected using avidin–
biotin, with goat anti-mouse immunoglobulin as the secondary antibody, followed by 
alkaline phosphatase-conjugated streptavidin and the chromogen diaminobenzidine or 
tetramethylbenzidine. Immunohistochemical sections were counterstained with 
hematoxylin.   
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 A semi-quantitative analysis of anatomical brain regions was carried out using a 
Leica DMLB microscope (Leica Wetzlar, Germany) from the following regions: superior 
frontal gyrus, middle frontal gyrus, anterior cingulate cortex, posterior cingulate cortex, 
superior and middle temporal gyri, superior parietal lobule, insular cortex, occipital 
cortex, amygdala, hippocampus, subiculum, parahippocampus, caudate nucleus, 
putamen, globus pallidus, thalamus, cerebellar hemisphere, dentate nucleus, substantia 
nigra, locus coeruleus, basis pontis, and inferior olivary nucleus.  The severity of 
neuropathologic changes were evaluated using a subjective scale: none = 0, mild = 1 
(+), moderate = 2 (++), and severe = 3 (+++).  
 
4.3 Results 
Neuropsychological Assessment 
The demographics, genetic status, and neuropsychological testing results at 
baseline for the [18F]FDG PET and  [11C]PIB PET are displayed in Table 3 and Table 4, 
respectively. Two participants with the F198S mutation (1 AC, 1 SC) were used for both 
studies. Although not statistically significant, more female than male participants were 
available for these studies across all groups.  
For the [18F]FDG PET study, no significant difference between groups was 
observed for sex, years of education, or the COWA test. Although not statistically 
significant, SCs were on average older than the NC and AC groups. As expected, all 
F198S mutation carriers had at least one valine at codon 129 of PRNP. A significant 
difference between groups was observed for the Mini-Mental State Exam (MMSE, 
p=0.026), Clinical Dementia Rating – Sum of Boxes (CDR-SB, p<0.001), and the Groove 
Pegboard Test, a high level motor processing task. Specifically, the NCs and ACs 
showed better cognition (higher MMSE; NC vs SC, p = 0.029; AC vs SC, p = 0.016), 
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lower clinical dementia rating (lower CDR-SB; NC vs SC, p<0.001; AC vs SC, p<0.001), 
and worse manual motor performance than the SCs (dominant hand: NC vs SC, p = 
0.009; AC vs SC, p = 0.043; non-dominant hand: NC vs SC, p = 0.0093; AC vs SC, p = 
0.027).  
For the amyloid study, significant differences were observed for age and 
education between NC and mutation carriers. As expected, the SC showed lower 
cognition and significantly impaired manual motor performance compared to ACs and 
NCs. 
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Table 3. Baseline demographic, neuropsychological, and motor performance data 
for the [18F]FDG PET study in GSS F198S. 
 NC AC SC p-value 
N 10 4 8  
Age (years) 40.5 (15.3) 30.5 (8.7) 47.9 (5.7) 0.72 
Sex (Male, Female) 7, 3 1, 3 3, 5 0.212 
Education (Years) 14.3 (2.8) 14 (1.8) 12.9 (1.5) 0.401 
Codon 129 status (MM, MV, VV) 2, 7, 1 0, 2, 2 0, 2, 6 0.064 
MMSE 28.7 (1.3) 29.5 (1) 26.8 (1.8) 0.026 
CDR-SB 0 0 0.56 (0.32) <0.001 
COWA* 40.3 (10.8) 45.3 (3.9) 33.5 (14) 0.673 
Groove Pegboard (Dom. Hand)** 69.8 (13) 63.8 (7.4) 110.6 (28.6) 0.008 
Groove Pegboard (Nondom. Hand)** 74.9 (15.6) 68 (11) 131.4 (36.4) 0.003 
NC = non-carriers; AC = asymptomatic carriers; SC = symptomatic carriers; M = 
methionine; V = valine; MMSE = Mini Mental State Examination; CDR-SB = Clinical 
Dementia Rating – Sum of Boxes; COWA = Controlled Oral Word Association test; Dom. 
= dominant; Nondom. = non-dominant. *Missing two symptomatic carriers. **Missing one 
symptomatic carrier. Mean (Standard Deviation).  
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Table 4. Baseline demographic, neuropsychological, and motor performance data 
for the [11C]PIB PET study in GSS F198S and P102L. 
 NC AC SC p-value 
N 9 4 1  
Age (Years) 66.1 (4.2) 44.3 (11.7) 41 <0.001 
Sex (Male, Female) 3, 6 1, 3 0, 1 0.312 
Education (years) 16.7 (1.7) 14 (1.4) 13 <0.001 
Mutation Status (F198S, P102L) 0, 0 1, 3 1, 0 n.a. 
MMSE* 28.9 (1.0)** 29.5 (0.6) 27 0.364 
CDR-SB 0.1 (0.2) 0 (0.0) 6 0.933 
COWA* 45.7 (8.0)*** 44 (6.1) 22 0.968 
Finger Tapping (Dom) n.a. 49.5 (8.8) 26 n.a. 
Finger Tapping (Non-Dom) n.a. 43.3 (8.8) 24 n.a. 
Grooved Pegboard (Dom) n.a. 70.3 (8.1) 154 n.a. 
Grooved Pegboard (Non-Dom) n.a. 80.3 (17.0) 149 n.a. 
NC = non-carrier; AC = asymptomatic carrier; SC = symptomatic carrier; MMSE = Mini-
Mental State Examination; CDR-SB = Clinical Dementia Rating-Sum of Boxes; COWA = 
Controlled Oral Word Association; n.a. = not available; Dom = dominant hand; Non-Dom 
= non-dominant hand). *Covaried for age, sex, and education. **Missing one non-carrier 
value; ***Missing three non-carrier values. Mean (standard deviation). 
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[18F]FDG PET 
The SC group showed hypometabolism in the cerebellum (right > left), bilaterally 
in the putamen and claustrum, and the left caudate head relative to NCs (Figure 7A-C). 
Other affected areas included the right substantia nigra, right red nucleus, and right 
thalamus, and others (Table 5). A similar hypometabolic pattern was observed in the 
cerebellum (right > left), left caudate head, right thalamus, and bilaterally in the putamen 
in SCs relative to ACs (Figure 7D-F).  
Unexpectedly, the AC group exhibited hypermetabolism rather than hypometabolism in 
the left caudate head, left putamen, left claustrum, and left superior temporal gyrus 
relative to NCs (Figure 7G-I). When PRNP-129M/V status was included as a covariate, 
similar results were observed in all analyses (data not shown). For all analyses, no 
significant clusters were observed in the opposite directions (SC>NC/AC, NC>AC).  
Due to the small sample size, a whole-brain voxel analysis could not be 
completed to determine the association of PRNP-129M/V status with glucose 
metabolism in these subjects. Instead, mean glucose uptake for the large significant 
clusters identified in the previous analysis in the bilateral cerebellum, right putamen, and 
left caudate were extracted in order to examine the effect of the PRNP-129 genotype on 
glucose uptake across diagnostic groups. Glucose metabolism in the left caudate head 
and right putamen of the AC group was increased in PRNP-129VV individuals relative to 
NC PRNP-129MV persons and showed a slight increase over NC PRNP-129MM 
persons in the NC group (Figure 8A-B). ). AC PRNP-129VV individuals did not show 
increased glucose metabolism in the cerebellum (Figure 8C). SC PRNP-129VV 
participants show reduced [18F]FDG uptake in the caudate and cerebellum relative to SC 
PRNP-129MV persons (Figure 8A-C).   
Next, we assessed if glucose metabolism in the caudate and putamen was 
associated with impaired memory and motor function, two predominant phenotypes 
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associated with the F198S mutation. [18F]FDG uptake in the left caudate and right 
putamen was associated with motor function (r = -0.53, p = 0.029; Figure 9) with lower 
[18F]FDG uptake associated with poorer motor function. However, the association was 
not significant when controlling for diagnosis or PRNP-129M/V status. No significant 
association was observed between [18F]FDG uptake in the striatal ROIs and memory 
performance (r = 0.41, p = 0.09).  
In order to evaluate the anatomical overlap between atrophic and metabolic 
group differences, a composite image of GM atrophy and hypometabolism of SCs 
relative to NCs was created. Significant overlap of the atrophic and metabolic patterns 
(NCs>SCs) was observed in the putamen (Figure 10). No other overlap was observed. 
Further evaluation of the right putamen revealed that GM atrophy exceeded 
hypometabolism in the SC group (Figure 10B). Also, the AC groups showed increased 
hypermetabolism, as described above, but no increases in GM in these regions (Figure 
10B). The atrophy and glucose uptake measurement of the right putamen were directly 
compared and showed a higher association (Figure 10C; r = 0.82; p < 0.001). 
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Figure 7. Hypometabolic regions in GSS F198S carriers and non-carriers.  
 Symptomatic carriers (SC) showed reduced [18F]FDG uptake in the (A) left 
caudate head, (B) putamen, and (C) cerebellum. Relative to asymptomatic carriers (AC), 
SCs showed reduced [18F]FDG uptake in the (D) caudate head, (E) putamen, and (F) 
cerebellum. ACs showed increased [18F]FDG uptake in the (G) left caudate head, (H) left 
putamen, and (I) the right superior temporal gyrus (BA22/39) relative to NCs. Group 
differences were are displayed at a voxel-wise threshold of p < 0.01 (uncorrected for 
multiple comparisons) and at a minimum cluster size (k) = 50 voxels. Age and sex were 
used as covariates.  
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Table 5. Anatomical distribution of reduced glucose metabolism in symptomatic 
GSS F198S carriers relative to non-carriers. 
   
MNI coordinates 
 
Location BA T-value x y z p-value 
L. Caudate Head 
 
6.59* −12 20 −4 0.000 
L. Putamen 
 
4.68 −32 −6 0 0.000  
3.88 −22 10 2 0.001 
R. Caudate Head 
 
2.71 14 20 −6 0.007 
R. Claustrum 
 
4.78 32 4 0 0.000 
R. Anterior Cerebellum 
(Culmen) 
 
5.52 6 −60 −30 0.000  
4.35 6 −70 −14 0.000  
3.7 4 −50 −12 0.001  
3.47 20 −40 −20 0.001 
R. Putamen 
 
3.32 20 10 12 0.002 
R. Substantia Nigra 
 
4.56 8 −20 −12 0.000 
R. Superior Temporal Gyrus 22 4.46 60 8 0 0.000 
R. Thalamus 
 
4.09 8 −10 −14 0.000  
2.68 2 −10 −2 0.008 
R. Thalamus or R. 
Parahippocampal gyrus 
 
4.14 14 −36 2 0.000 
BA = Brodmann area; L. = left; R. = right 
p-value < 0.01, uncorrected; *Significant cluster for p < 0.05 at FWE-corrected 
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Figure 8. Quantitation of the PRNP-M129V haplotype effect on glucose 
hypometabolism in symptomatic and asymptomatic GSS F198S mutation carriers 
and non-carriers.  
In the left caudate (A) and right putamen (B) of the asymptomatic carrier (AC) 
group, PRNP-129VV participants show more hypermetabolism relative to PRNP-129MV. 
In all ROIs (A-C) for the symptomatic carrier (SC) group, PRNP-129VV participants 
show reduced [18F]FDG uptake relative to PRNP-129MV participants. 
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Figure 9. Motor function is correlated with [18F]FDG uptake in the caudate and 
putamen.  
(A) Worse motor function, as measured by the groove pegboard test, was 
associated with lower [18F]FDG uptake in the striatum (caudate and putamen).  
r = -0.53 
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Figure 10. Grey matter and glucose hypometabolism in symptomatic GSS F198S 
mutation carriers and non-carriers.  
 (A) Anatomical overlap (purple) of grey matter (GM) atrophy (blue) and glucose 
hypometabolism (red) in symptomatic GSS F198S symptomatic carriers relative to non-
carriers (NC) was observed in the striatum. (B) Mean GM density and [18F]FDG SUVR 
values from the right putamen were significant associated with each other, covaried for 
age, sex, and total intracranial volume (rp = 0.82, p<0.001). Linear fits are shown for 
each diagnostic group: non-carrier (NC), solid line; asymptomatic carrier (AC), dashed 
line; symptomatic carrier (SC), dotted line. The association was primarily driven by the 
NC and AC groups.  
A 
B C 
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[11C]PIB PET 
No apparent visual differences in baseline [11C]PiB PET uptake were observed 
between the NCs, the ACs, and the SC individual, suggesting minimal [11C]PiB binding 
in ACs and even in the symptomatic individual (Figure 11A-C).  MRI of the symptomatic 
carrier revealed a mild degree of atrophy of the cerebellar cortex. Quantitative regional 
analysis did not reveal any significant difference in [11C]PiB retention in either global 
cortical GM or cerebellum between mutation carriers (SC or ACs) and NCs (Figure 11D). 
Qualitative observation of the baseline and longitudinal follow-up scans for the 3 ACs did 
not show any appreciable increase in [11C]PiB signal over time (Figure 12A-C). This 
observation was supported by minimal longitudinal change in mean [11C]PiB SUVR in 
cortical GM and cerebellum ROIs (Figure 12D). 
Moderate (++) to severe (+++) neuronal loss was observed in the superior frontal 
and cingulate gyri, putamen, caudate nucleus, superior and middle temporal gyri, 
hippocampus, subiculum, entorhinal cortex, superior parietal lobule, calcarine cortex, 
cerebellum, midbrain, and spinal cord (anterior horn cells; data not shown).  In addition, 
moderate (++) axonal and myelin loss was observed in the superior frontal and cingulate 
gyri, caudate nucleus and putamen, superior parietal lobule, superior and inferior 
temporal gyri, occipital lobe, cerebellar white matter, and spinal cord (dorsal 
spinocerebellar tract, anterior spinocerebellar tract, lateral corticospinal tract, posterior 
columns; data not shown).   
Pathologic prion protein (PrP) (Figure 13A, C) and Thioflavin S positive (Figure 
13E) unicentric and multicentric plaques (severe, +++) were observed in the superior 
frontal and cingulate gyri, putamen, caudate nucleus, superior and middle temporal gyri, 
hippocampus, entorhinal cortex, superior parietal lobule, calcarine cortex, cerebellum, 
and midbrain.   
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Tau-immunopositive neurofibrillary tangles (+++) (Figure 13B, D) and neuropil 
threads (+++) (Figure 13B, D) were observed in the superior frontal and cingulate gyri, 
entorhinal cortex, amygdala, substantia innominata, superior and middle temporal gyrus, 
thalamus, superior parietal lobule, middle frontal gyrus, posterior cingulate gyrus, 
precuneus, inferior parietal lobule, and substantia nigra. Figure 13 is from frontal cortex 
but is representative of the cerebral cortex. PrP and tau pathologies were more 
prominent in the deeper layers of the cerebral cortex. In the cerebellum, there was a 
severe (+++) loss of neuronal perikarya which was associated with numerous (+++) PrP-
immunopositive plaques. The white matter showed extensive (+++) axonal loss. Plaques 
were observed throughout all layers of the cerebellar cortex (Figure 14A-C). No Aβ 
immunopositive deposits were seen. 
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Figure 11. Baseline [11C]PiB PET in F198S and P102L carriers and non-carriers.  
 [11C]PiB SUVR images for (A) a symptomatic carrier, (B) asymptomatic carriers 
(n=4), and (C) non-carriers (n=9). Note that B and C are the average image across 
participants within each group, while A is a single participant. No notable visual 
differences in [11C]PiB SUVR images were observed between the symptomatic carrier, 
asymptomatic carriers, and non-carriers. (D) [11C]PiB SUVR levels in the global cortical 
grey matter and the whole cerebellum in non-carriers and mutation carriers are 
displayed. No significant difference was observed in global cortex and whole cerebellum 
[11C]PiB SUVR between non-carriers and mutation carriers. 
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Figure 12. Baseline [11C]PiB PET in F198S and P102L asymptomatic carriers.  
 Baseline (left) and follow-up (right) [11C]PiB SUVR images for 3 asymptomatic 
carriers (2 P102L (A, B), 1 F198S (C)). No appreciable increase in [11C]PiB from the 
baseline to the follow-up scan was observed in any of the participants. (D) Quantitation 
of mean [11C]PiB SUVR in the cortical grey matter and whole cerebellum supported this 
qualitative observation. 
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Figure 13. Extracellular PrP deposits and intracellular tau aggregates shown by 
immunohistochemistry and Thioflavin S in the frontal cortex of the PRNP F198S 
carrier.  
3F4 immunohistochemistry reveals unicentric and multicentric PrP 
immunopositive plaques (A, C). AT8 immunohistochemistry reveals tau-immunopositive 
neurons and neuropil threads (B, D). Plaques and neurofibrillary tangles are fluorescent 
with Thioflavin S. PrP deposits and tau aggregates are shown at two different 
magnifications (A, B = 50X total magnification and C-E = 100X total magnification). 
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Figure 14. Extracellular PrP deposits shown by immunohistochemistry and 
Thioflavin S in the cerebellum of the PRNP F198S carrier.  
3F4 immunohistochemistry reveals unicentric and multicentric PrP 
immunopositive plaques throughout the cerebellar cortex (A, C). Plaques are fluorescent 
with Thioflavin S (B). PrP deposits are shown at two different magnifications (A = 10X 
total magnification and B = 100X total magnification). Thioflavin S fluorescent plaques 
are shown at 100X total magnification.  
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4.4 Discussion 
The aim of this study was to (1) assess the glucose metabolism patterns in GSS 
subjects with the F198S mutation, and (2) determine the feasibility of using [11C]PiB PET 
to detect APrP deposits in individuals at risk for developing GSS, who are carriers of the 
PRNP P102L or F198S mutations. To our knowledge, this is the largest study to 
investigate  [18F]FDG uptake in GSS subjects with the F198S mutation and the largest 
PET study investigating [11C]PiB in individuals at risk for GSS, and the first to evaluate 
[11C]PiB in GSS subjects with the F198S mutation. Furthermore, this is the first study 
evaluating individuals at risk for a hereditary prion disease longitudinally using [11C]PiB 
PET. 
 
[18F]FDG PET Findings 
We observed hypometabolism in the left caudate head and bilaterally in the 
putamen and cerebellum in SCs relative to both the NC and AC groups. However, 
atrophy in the putamen largely overlapped with the metabolic pattern in SCs relative to 
NCs. Hypermetabolism was observed in AC group relative to the NC group in the left 
caudate head, putamen, claustrum, and superior temporal gyrus. Additionally, PRNP-
129VV participants showed reduced [18F]FDG uptake relative to PRNP-129MV carriers. 
Reduced metabolism in the caudate and putamen was also associated with poorer 
motor function. Abnormal glucose metabolism in these regions may underlie the 
cognitive and motor dysfunction observed in individuals with the F198S mutation and 
supports previous reports suggesting that PRNP-129VV participants have an earlier 
disease onset.  
Increased glucose uptake in the left caudate head and putamen in the ACs 
relative to NCs may be suggestive of an increased metabolic demand or a 
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compensatory mechanism due to degeneration of neurons, which occurs early in the 
disease process. Considering that the hypermetabolism precedes symptom onset and is 
observed in the same regions that show hypometabolism in SCs suggests that we may 
be capable of detecting functional brain changes early in the disease course. 
Hypermetabolism has also been observed in healthy, cognitively normal individuals in 
regions known to later have high amyloid-beta deposition [206, 207]. Future studies to 
determine if this hypermetabolism is dependent on APrP or tau deposition in GSS 
F198S carriers are warranted.  
The reduced glucose metabolism observed in the dorsal striatal and cerebellar 
regions in SCs relative to ACs and NCs was associated with impaired motor function. 
Further, the glucose hypometabolism is observed in anatomical regions with previously 
described to have significant deposition of PrP-amyloid and/or tau in subjects with the 
F198S mutation [191]. These findings are also supported by other PET studies 
investigating other GSS mutations and familial prion diseases [194-197, 208]. Striatal 
hypometabolism in SCs has also been observed in other tauopathies associated with 
Parkinsonism, including progressive supranuclear palsy (PSP) and corticobasal 
degeneration (CBD) [209]. Neuroimaging studies in familial tauopathies are uncommon 
considering the rarity of these diseases, but one familial PSP study found bilateral 
striatal hypometabolism in SCs relative to controls [210]. Thus, our findings are similar to 
those found in other tauopathies, including those with parkinsonism. However, in this 
study, a significant associated between GM atrophy and hypometabolism in the putamen 
was observed suggesting that the metabolic activity observed in this region may be 
partially due to neuronal loss in the SC group. 
Although the sample size was too small to conduct a statistical analysis, glucose 
metabolism was lower in PRNP-129VV SCs in striatal and cerebellar regions, further 
supporting the notion that these subjects have a more aggressive disease presentation. 
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PRNP-129VV AC F198S carriers showed higher metabolism in the caudate and 
putamen, suggesting that this hypermetabolism may be antecedent to symptom onset as 
the PRNP-VV AC individuals are likely to be closer to the earlier age of onset seen in 
these individuals. However, this trend was not observed in the cerebellum, a region 
devoid of tau deposition in F198S mutation carriers [211]. One hypothesis may be that 
the hypermetabolism observed in caudate and putamen may be mediated by tau 
pathology, as tau and hypermetabolism are both observed in the striatum but not in the 
cerebellum.  
A small number of F198S mutation carriers had follow-up scans. The rate of 
glucose uptake remained relatively stable over time which is similar to the AC F198S 
participant reported in Kepe et al. (2010) [196] Moreover, these findings are in 
agreeance with post-mortem findings in which moderate atrophy is observed in the 
cortex and moderate-to-severe atrophy is observed in the cerebellum [211]. These 
findings suggest that changes in glucose utilization and atrophy may be the primary 
drivers of dysfunction in this family.  
 
[11C]PiB PET Findings 
 [11C]PiB PET imaging is highly informative for the in vivo early detection of 
deposits of fibrillar Aβ and possibly for the differential diagnosis of Alzheimer’s disease 
versus other dementias. Our results show that there was no appreciable [11C]PiB 
retention in one symptomatic and four asymptomatic mutation carriers [212]. 
Considering the fact that the asymptomatic mutation carriers were close to the age of 
disease onset of their parents, it is conceivable that APrP might have been already 
present in some of the AC individuals and particularly in the PRNP F198 symptomatic 
case.  
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The findings in our sample are consistent with other reports that also show no 
[11C]PiB retention in participants with a PRNP mutation. Most of these studies 
investigated [11C]PiB PET in a single subject, with one study reporting a slightly larger 
sample size [201]. Our data extend these preliminary findings in a larger cohort of 
participants. However, other studies have suggested that alternative amyloid tracers, 
including [18F]FDDNP and [11C]BF-227, show some sensitivity for GSS APrP, opening up 
the possibility that the various amyloid radioligands have unique binding properties with 
respect to amyloid type [196, 204].  
 The apparent lack of [11C]PiB retention was not likely due to an absence of APrP 
in the PRNP mutation carriers studied. No [11C]PiB retention was observed in the 
symptomatic individual, who had significant APrP deposition in cortical and cerebellar 
regions, as shown in the neuropathologic specimen obtained 46 months after the PET 
study. The impairment in neuropsychological and motor performance of this patient at 
the time of the PET scan also suggested a significant dysfunction of cortical, cerebellar, 
and striatal function likely due to APrP deposition. Further, in cases carrying the F198S 
mutation APrP deposition begins prior to significant clinical symptoms (BG unpublished 
observations), suggesting that the older F198S AC in this study may also have had APrP 
deposits that were not detected by [11C]PiB PET. In addition, in some cases Aβ is 
observed around the APrP plaques [213, 214]. However, we were unable to detect this 
in vivo using [11C]PiB PET despite its known sensitivity for Aβ. MRI data of the SC 
obtained at the time of the [11C]PiB PET imaging (data not shown), revealed atrophy of 
the cerebellar cortex, a finding supporting the view that extensive PrP amyloid deposits 
were already present 46 months before death.  Given the lack of appreciable specific 
signal in the symptomatic GSS patient, we suggest that [11C]PiB may not bind to APrP 
nor is there enough Aβ deposition to be detected by [11C]PiB PET. The apparent lack of 
ability of [11C]PiB to detect APrP plaques in GSS could be due to several factors, 
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including altered tracer distribution and metabolism in this sample. However, the most 
likely possibility is that the APrP plaques possess a different conformational structure 
from the Aβ plaques, which may not be conducive to [11C]PiB binding despite their 
sensitivity to thioflavin on neuropathologic assessment.   
 
Study Limitations 
The limitation presented in these studies included small sample size. This 
precluded statistical analysis for the effect of the PRNP-129M/V status on glucose 
metabolism and the sample of symptomatic carriers who are known to have extensive 
neuropathological APrP deposits. Future studies using a larger sample of affected 
individuals would be desirable, as these participants would have significant amounts of 
the APrP deposits and would allow us to better investigate the effect of PRNP-129M/V 
status. Additionally, due to the small sample size, we were unable to run separate 
analyses for the MRI study so both 1.5T with 3T scans were combined into one group. 
We also did not use a standard partial volume correction method to account for possible 
atrophy. In addition, evaluation of other amyloid tracers alone, or in combination with 
[11C]PiB may potentially provide valuable insight into the timing and distribution of APrP 
deposition in this population, as well as the relative sensitivity of different amyloid tracers 
for detection of the various forms of amyloid. Finally, PET studies with recently 
developed tau radiotracers in individuals affected by GSS associated with the PRNP 
F198S, which are known to have neurofibrillary tangles, in combination with amyloid 
tracers - could be useful for the in vivo analysis of pathophysiological processes 
underlying disease symptoms and for tracking of disease progression.  
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Summary 
Multi-modal neuroimaging can offer insight into brain structure and function 
underlying the phenotypes of disease. We identified striatal and cerebellar 
hypometabolism in symptomatic GSS F198S subjects, with the striatal regions also 
showing hypermetabolism in asymptomatic carriers of the F198S mutation. 
Homozygosity for valine at PRNP-129 was associated with lower metabolism in the SC 
group but higher metabolism in the AC group. These findings suggest that dysfunctional 
metabolism in the striatum and cerebellum may underlie the cognitive and motor 
dysfunction seen in GSS participants with the PRNP F198S mutation. Overall these 
findings suggest that glucose metabolism measured using [18F]FDG PET is a potential 
tool for early prognostication of future clinical decline in individuals with the GSS F198S 
mutation. Additionally, we found no evidence for significant [11C]PiB retention in 
participants carrying the PRNP P102L or F198S mutations, regardless of diagnostic 
status. Our findings agree with previous reports and suggest that [11C]PiB may be 
clinically useful for ruling out AD in people at risk for GSS, but would provide no utility for 
detecting APrP pathology in these patients.  
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Chapter 5: Neuroimaging Correlates of Peripheral Markers of Neuronal Injury 
5.1 Introduction 
 Understanding the underlying pathological processes of Alzheimer’s disease 
(AD) and developing reliable biomarkers are critical to identify the causes and 
pathogenesis of AD. Both in vivo and post-mortem studies have shown that pathological 
tau is correlated with neurodegeneration, disease severity, and cognitive impairment 
[87]. Likewise, in vivo central measures of tau in cerebrospinal fluid (CSF) also correlate 
with post-mortem tau pathology and are increased in AD patients relative to those in a 
prodromal stage of AD referred to as mild cognitive impairment (MCI) and cognitively 
normal controls (CN), aiding prediction of disease progression [215, 216]. However, CSF 
collection is regarded as invasive, leading researchers to search for alternative methods 
to monitor MCI and AD such as blood biomarkers.   
A recent meta-analysis reported plasma tau as the only blood-based biomarker 
to delineate AD from controls [217]. Fortunately, a new ultrasensitive technique, the 
single molecule array (Simoa) platform, was developed capable of detecting tau at low 
concentrations in plasma [127]. Similar to CSF, plasma tau concentrations were found to 
be significantly higher in AD relative to MCI and CN. Although not significantly different, 
plasma tau was also higher in MCI compared to CN [128, 218, 219]. However, a large 
overlap was observed between the MCI and CN groups suggesting plasma tau may not 
be suitable as a diagnostic marker. Further, the correlation between plasma tau and 
CSF tau and hippocampal volume was weak or non-existent [128, 218, 219]. Mattsson 
et al. (2016) did show evidence that plasma tau was associated with a greater 
longitudinal decline in hippocampal volume and Dage et al. (2016) showed that high 
levels of plasma tau were associated with lower cortical thickness in AD-specific brain 
regions [128, 218]. These results suggest plasma tau may be correlated with atrophy of 
AD-specific regions as the disease progresses. 
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Neurofilament light chain (NFL) is a scaffolding protein of myelinated axons. 
Similar to CSF and plasma levels of tau, a microtubule-associated protein that is a main 
pathological hallmark of Alzheimer’s disease (AD), CSF and plasma levels of NFL have 
been shown to increase after neural injury in several neurodegenerative disorders such 
as AD, Progressive Supranuclear Palsy, and Frontotemporal Dementia [18, 43, 130, 
220]. Very recently, Mattsson et al. (2017) released the first large study investigating 
plasma NFL in AD [129]. Plasma NFL was significantly increased in AD and in β-amyloid 
positive mild cognitive impairment (MCI) subjects. Additionally, plasma NFL level was 
correlated with the level of CSF NFL, suggesting it may be a good peripheral marker of 
central NFL levels. Plasma NFL was also associated with a decline in hippocampal 
volume and cortical thickness in AD-specific brain regions over time. This group had also 
reported similar findings with plasma tau; however, no correlation was observed 
between plasma and CSF levels of tau [128]. When directly compared, plasma NFL also 
performed better then plasma tau at discriminating AD from controls. However, plasma 
NFL concentrations largely overlapped across diagnostic groups and is also increased in 
other neurodegenerative disorders. Thus, they suggested that plasma NFL, like plasma 
tau, cannot alone be used as a diagnostic marker. Even so, the findings reported by 
Mattsson et al. suggest that NFL may be another target protein for peripheral 
measurement of neural injury and may show be more robust than tau.  
The goal of this study was to look at two markers of axonal degeneration, tau and 
NFL, in association with neurodegeneration by MRI. We also aimed to determine if 
plasma and CSF concentrations of tau and NFL were related to atrophy in similar brain 
regions. We hypothesize that plasma tau and NFL will be inversely correlated with grey 
matter density (GMD), a measure of grey matter atrophy as seen in the previous reports 
of plasma tau, plasma NFL, and measures of atrophy [221]. Secondly, we hypothesize 
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that plasma total-tau (t-tau) and CSF t-tau, and plasma NFL and CSF NFL will be related 
to similar regions of atrophy. 
 
5.2 Materials and Methods 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) 
Data used in the preparation of this article were obtained from the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was 
launched in 2003 as a public-private partnership, led by Principal Investigator Michael 
W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic 
resonance imaging (MRI), positron emission tomography (PET), other biological 
markers, and clinical and neuropsychological assessment can be combined to measure 
the progression of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). 
Written informed consent was obtained from all participants according to the Declaration 
of Helsinki. 
 
Plasma Tau Collection and Quality Control 
Peripheral plasma tau concentrations were measured for 581 non-Hispanic 
Caucasian participants using the Single Molecule array (Simoa) technique with the 
Human Total Tau assay (Human Total Tau 2.0 kit, Quanterix Corp, Boston, MA, USA). 
This assay and the plasma tau characteristics for ADNI have been previously described 
[127, 128]. In brief, the assay uses two monoclonal antibodies which bind to the N-
terminus and mid-region of tau, and measures both normal and phosphorylated tau 
protein. Values are given as pg/mL. A total of 38 samples had plasma concentration 
below the Limit of Detection (LOD) or below the Lower Limit of Quantification (LLOQ) 
and were removed from further analysis. An additional four samples had missing values. 
To reduce the possible effect of extreme outliers on statistical analysis, the mean and 
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standard deviation (SD) of plasma tau were calculated; participants with a value more 
than three SDs above or below the mean value were regarded as outliers and removed 
from further analysis. This resulted in the removal of eight participants. Only participants 
with a MRI scan were included, leaving 508 participants for the plasma tau study (166 
CN, 174 MCI, 168 AD). 
 
Plasma NFL Collection and Quality Control 
 Plasma NFL concentrations were measured for 560 non-Hispanic Caucasian 
participants using an NFL assay (UmanDiagnostics) and transferred to the Simoa 
platform using a home brew kit (Simoa Homebrew Assay Development Kit; Quanterix 
Corp., Boston, MA, USA) as previously described [129, 222]. No samples were below 
the limit of detection and all samples were within the limit of quantification. All subjects 
with valid plasma NFL samples were used in order to extend the findings reported in 
Mattson et al. (2017) [18].  
 
CSF Collection and Quality Control 
CSF analytes (Aβ1-42, t-tau and p-tau181p) were measured using the multiplex 
xMAP Luminex platform (Luminex Corp, Austin, TX) with Innogenetics (INNO-BIA 
AlzBio3; Ghent, Belgium; for research use-only reagents) immunoassay kit-based 
reagents. To reduce the possible effect of outliers on statistical analysis, the mean and 
standard deviation of CSF analytes were calculated and participants with at least one 
analyte value more than three SD below or above the mean value of each of CSF 
variable were regarded outliers and removed from the analysis. This resulted in 341 
valid CSF samples. For the MRI-CSF study, only participants with a CSF value for both 
t-tau and p-tau were included in the CSF study leaving 331 participants available (91 
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CN, 158 MCI, 82 AD). Participants were classified as amyloid positive (Aβ+) if CSF Aβ1-
42 <192pg/mL.  
CSF NFL was measured using an ELISA (NF-light ELISA kit, UmanDiagnostics 
AB, Umea, Sweden) as previously described [220, 223]. We removed eight Aβ-negative 
(Aβ-) participants with AD from analysis. In total, 367 participants had CSF NFL samples 
available for analysis (104 CN, 180 MCI, 83 AD).  
 
MRI Scan Processing 
All participants had baseline 1.5T magnetization-prepared rapid gradient-echo 
(MPRAGE) images downloaded from the ADNI LONI site (http://adni.loni.usc.edu/). 
Scan processing with voxel-based morphometry (VBM) in Statistical Parametric Mapping 
8 (SPM8; Wellcome Trust Centre for Neuroimaging, 
http://www.fil.ion.ucl.ac.uk/spm/software/spm8/) and quality control were done as 
previously described [177]. Briefly, scans were co-registered to a T1-weighted template 
and segmented into different tissue classes (GM; white matter, WM; CSF). GM maps 
were normalized to MNI (Montreal Neurologic Institute) space without modulation as 1 x 
1 x 1 mm voxels and smoothed with an 8 mm Gaussian kernel to create GM density 
(GMD) images for further analysis. GMD is the average concentration of grey matter 
around the voxel thus, a reduction of GMD serves as a proxy of atrophy [221]. 
 
Image Analysis 
 Voxel-wise linear regression models in SPM8 were used to evaluate the 
relationship between central (CSF) and peripheral (plasma) measures of tau and NFL 
with GMD. Age, sex, education, APOE status (ε4 carrier or ε4 non-carrier), and total 
intracranial volume were included as covariates in the regression models. Analyses were 
done with and without diagnosis as an additional covariate. An explicit GM mask was 
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applied to the MRI scans to restrict the search area for the statistical analysis. Significant 
results were displayed at a voxel-wise p < 0.05 (family-wise error (FWE) correction for 
multiple comparisons) and with a minimum cluster size (k) of 100 voxels. If no brain 
regions survived correction for multiple comparisons, then a slightly less stringent voxel-
wise p-value of 0.001 (uncorrected for multiple comparisons) was used. To determine if 
there were any overlapping brain regions significantly correlated to plasma and CSF 
analytes of tau or NFL, a composite image was created in SPM8. Anatomical regions 
were defined by using the x-y-z coordinates for the most significant voxel within each 
cluster. These coordinates were entered into the Talairach daemon 
(http://www.talairach.org/daemon.html) to receive the anatomical names for the GM 
regions closest to that coordinate [4]. 
 
Statistical Analysis 
SPSS V24.0 was used for all statistical analyses. CSF t-tau, p-tau, NFL, and 
plasma NFL values were log transformed in order to achieve normal distribution. Plasma 
tau values were normally distributed and thus absolute values were used for analysis; 
results were unchanged when transformed plasma values were used. The association of 
sex, APOE ε4 status, and Aβ positivity with diagnostic group was assessed using a 
Pearson chi-squared test. ANOVA was used to assess the relationship of age, 
education, Mini-Mental State Exam (MMSE), Clinical Dementia Rating Scale – Sum of 
Boxes (CDR-SB), plasma tau, and CSF analytes with diagnostic status. Post-hoc 
pairwise differences among diagnostic groups were assessed using a Bonferroni 
correction for multiple comparisons. The MarsBaR toolbox in SPM8 was used to extract 
mean GMD from significant clusters from the voxel-wise results for further 
characterization of the results [224].   
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Regional Analysis 
In order to determine whether replication of the Dage et al. (2016) plasma tau 
findings was observed, we analyzed the ADNI data using a similar method as was 
described in the manuscript [218]. Briefly, MRI scans from all participants were 
processed using Freesurfer version 5.1 to extract mean cortical thickness from the 
bilateral entorhinal cortex, inferior temporal gyri, middle temporal gyri, and fusiform [225, 
226]. These cortical thickness estimates were averaged to create an AD signature 
cortical thickness measure, as in Dage et al. (2016) [218]. Abnormal cortical thickness 
was defined as a mean thickness below the 90th percentile of the AD participants as 
previously described [218, 227], resulting in an abnormal cortical thickness cut-off of 
<2.77 mm. As in Dage et al. (2016), we sought to investigate the association between 
plasma tau and the probability of having abnormal cortical thickness, as defined above, 
in MCI and CN participants (n=339), as well as in the full sample. A logistic regression 
was used to estimate this association both unadjusted (model 1) and adjusted for age, 
sex, education, and APOE ε4 status (model 2), as was done by Dage et al (2016) [218].  
 
5.3 Results 
Demographic and Clinical Characteristics 
There was a near equal number of participants in each diagnostic group for both 
the plasma tau and NFL studies (Table 6). Significant differences among diagnostic 
groups were observed for all demographic and clinical characteristics examined except 
for age. As expected, for both the plasma NFL and tau study, the AD group had the 
highest percentage of APOE ε4 carriers, followed by the MCI group. Significant 
differences in the mean MMSE and CDR-SB among the diagnostic groups, with the AD 
group showing the most impairment and the MCI group showing intermediate 
impairment between AD and CN (p < 0.001 for both the plasma tau and plasma NFL 
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study). Plasma tau, plasma NFL, CSF t-tau, CSF p-tau and CSF NFL were significantly 
different between groups, with the AD group showing significantly higher concentrations 
compared to MCI and CN. The number of Aβ+ participants was also significantly 
different among diagnostic groups (p < 0.001). 
Similar to previous reports, the mean plasma tau concentrations in the MCI and 
CN groups were nearly equal. There was no significant difference in demographic and 
clinical characteristics for the 35 ADNI participants whose samples were excluded 
compared to those included in the present study (Table 7). However, as expected the 
plasma tau was significantly different between the included/excluded groups since the 
excluded plasma tau samples all had a value <1. Plasma tau levels between diagnostic 
groups for the excluded samples was not statistically different (p=0.202).   
 
Plasma Tau Association with Cortical Thickness 
A recent report by Dage et al. (2016) found that high levels of plasma tau were 
associated with lower cortical thickness in the entorhinal, inferior temporal, middle 
temporal, and fusiform of MCI and controls [218]. However, we did not find a significant 
association of plasma tau levels with abnormal cortical thickness in either the unadjusted 
or adjusted models (Table 8).  
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Table 6. Demographic and clinical characteristics for the plasma tau and NFL studies.  
 Plasma Tau Study Plasma NFL Study 
 CN MCI AD p-value CN MCI AD p-value 
N 166 174 168 - 184 188 175  
Age (years) 75.2 (5.1) 74.1 (7.6) 75.3 (7.3) 0.789 75.3 (4.9) 74.1 (7.5) 74.7 (7.3) 0.26 
Sex (M, F) 95, 71 115, 59 87, 81 0.025 104, 80 124, 64 89, 86 0.013 
Education (years) 16.1 (2.7) 15.8 (3) 14.8 (3.1) <0.001 16 (2.7) 15.8 (3) 14.7 (3.1) <0.001 
% APOE ε4+ 27.1% 54% 67.9% <0.001 27.2% 53.2% 68.6% <0.001 
MMSE 29.1 (1) 26.9 (1.8) 23.2 (2) <0.001 29.1 (1) 26.9 (1.8) 23.2 (2) <0.001 
CDR-SB 0 (0.1) 1.6 (0.9) 4.3 (1.6) <0.001 0 (0.1) 1.6 (0.9) 4.3 (1.6) <0.001 
% Amyloid+* 35.2% 73.9% 93.8% <0.001 34.8% 74.1% 100% <0.001 
CSF t-tau 
pg/mL** 
65.7 (24.7) 97.6 (48.6) 121.2 (52.4) <0.001 - - - - 
CSF p-tau 
pg/mL** 
22.3 (10.5) 34.3 (16.2) 41.5 (18.5) <0.001 - - - - 
Plasma tau 
pg/mL 
2.7 (1) 2.8 (1.2) 3.1 (1.3) 0.002 - - - - 
Plasma NFL 
pg/mL 
- - - - 35 (21.8) 42.2 (28.6) 51.1 (27) <0.001 
CSF NFL 
pg/mL*** 
- - - - 
1090.4 
(425.8) 
1489.6 
(884.6) 
1694.5 
(843.1) 
<0.001 
 
CN = cognitively normal; MCI = mild cognitive impairment; AD = Alzheimer’s disease; M = male; F = female; APOE = 
apolipoprotein; MMSE = mini-mental state exam; CDR-SB = clinical dementia rating-sum of boxes; CSF = cerebrospinal fluid. 
Mean (standard deviation). *n = 91 CN, 157 MCI, 81 AD for plasma tau study; n = 92 CN, 162 MCI, 80 AD for plasma NFL 
study. **n = 91 CN, 158 MCI, 82 AD. ***n = 104 CN, 180 MCI, 83 AD.
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Table 7. Demographic and clinical characteristics for the 35 excluded ADNI samples from the plasma tau study.  
 
  CN_Exc CN_Inc p-value MCI_Exc MCI_Inc p-value AD_Exc AD_Inc p-value 
N 14 166  - 11 174 - 10 168 - 
Age (years) 75.9 (2.5) 75.2 (5.1) 0.65 75.4 (6.4) 74.1 (7.6) 0.6 70.7 (5.8) 75.3 (7.3) 0.06 
Sex (M, F) 6, 8 95, 71 0.23 7, 4 115, 59 0.87 4, 6 87, 81 0.47 
APOE ε4 (% ε4 
positive) 
28.6% 27% 0.91 27% 54% 0.09 60% 68% 0.61 
MMSE 29.1 (.9) 29.1 (1) 0.89 26.9 (2.4) 26.9 (1.8) 0.99 23.6 (1.5) 23.2 (2) 0.59 
CDR-SB 0.07 (0.2) 0 (0.1) 0.3 1.4 (0.8) 1.6 (0.9) 0.51 4.4 (1.2) 4.3 (1.6) 0.9 
Plasma tau 
pg/mL 
0.5 (0.2) 2.7 (1) <0.001 0.5 (0.3) 2.8 (1.2) <0.002 0.7 (0.2) 3.1 (1.3) <0.001 
CSF t-tau 
pg/mL* 
77.5 (43.2) 65.7 (24.7) 0.19 91.5 (37.1) 97.6 (48.6) 0.64 94.9 (66.7) 121.2 (52.4) 0.19 
CSF p-tau 
pg/mL* 
28.1 (17.9) 22.3 (10.5) 0.24 28.6 (12.6) 34.3 (16.2) 0.23 33.5 (21.3) 41.5 (18.5) 0.26 
Amyloid (-/+)** 6, 5 59, 32 0.58 4, 7 41, 116 0.43 1, 5 5, 76 0.29 
 
CN = cognitively normal; MCI = mild cognitive impairment; AD = Alzheimer’s disease; Exc = excluded from current study; Inc 
= Included in current study; M = male; F = female; APOE = apolipoprotein; MMSE = mini-mental state exam; CDR-SB = 
clinical dementia rating-sum of boxes; CSF = cerebrospinal fluid. Amyloid + if CSF Aβ ≤ 192 pg/mL. Mean (standard 
deviation). Significant p-values < 0.05 are italicized. *CN_Exc = 11; CN_Inc = 91; MCI_Exc = 11; MCI_Inc = 158; AD_Exc = 6; 
AD_Inc = 8. **Missing 1 MCI_Inc and 1 AD_Inc.
  
8
9
 
Table 8. Association of plasma tau levels with cortical thickness in AD-specific brain regions. 
CN = cognitively normal; MCI = mild cognitive impairment; AD = Alzheimer’s disease; OR = odds ratio; CI = confidence 
interval. Model 1 is unadjusted. Model 2 is adjusted for age, sex, education, and APOE ε4 status. The cortical thickness 
measure is an average of the entorhinal, fusiform, inferior temporal, and middle temporal regions of interest. 
 
abnormal cortical 
thickness (<2.77) 
Model 1 Model 2 
  
N OR (95% CI) p-value N OR (95% CI) p-value 
CN+MCI Continuous 339 0.95 (0.78 - 1.16) 0.62 339 0.94 (0.77 – 1.15) 0.55  
Quartiles 
      
 
1 339 reference 
 
339 reference 
 
 
2 
 
0.79 (0.44 - 1.42) 0.43 
 
0.72 (0.39 – 1.32) 0.29  
3 
 
0.89 (0.5 - 1.6) 0.69 
 
0.86 (0.47 - 1.57) 0.61  
4 
 
0.93 (0.51 - 1.73) 0.83 
 
0.88 (0.47 - 1.67) 0.7 
CN+MCI+AD Continuous 507 1.12 (0.96 - 1.31) 0.16 
 
1.1 (0.93 - 1.3) 0.27  
Quartiles 
      
 
1 507 reference 
 
507 reference 
 
 
2 
 
1 (0.61 - 1.66) 0.98 
 
0.87 (0.52 - 1.47) 0.61  
3 
 
0.96 (0.58 - 1.59) 0.88 
 
0.85 (0.5 - 1.43) 0.53  
4 
 
1.49 (0.89 – 2.5) 0.13 
 
1.36 (0.79- 2.32) 0.27 
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Voxel-based MRI Analysis 
Across all participants, a significant association between higher plasma tau and 
lower GMD in several brain regions was observed, including in the middle, inferior, and 
superior temporal gyrus, parahippocampus, hippocampus, fusiform, uncus, precuneus, 
thalamus, caudate, putamen, and middle and inferior frontal gyrus (Figure 15A-D, voxel-
wise p<0.001 (uncorrected), k=100 voxels). As would be expected, AD participants had 
lower mean GMD in the larger clusters identified (parahippocampus and striatum; 
Figure16A). When controlling for diagnosis, a significant association between plasma tau 
and GMD was still observed in the right thalamus and bilaterally in the striatum (Figure 
15C-D). No voxels, either with or without diagnosis as a covariate, survived correction 
for type I error rate. No significant clusters were observed in the positive/unexpected 
direction (data not shown). 
High plasma NFL was associated with low GMD in the frontal, temporal, insular, 
and occipital cortices (Figure 17, voxel-wise p<0.05 (FWE corrected), k=100 voxels). 
When diagnosis was added a covariate, the association of high plasma NFL with low 
GMD was more localized to the medial temporal lobe (MTL), including in the 
hippocampus and parahippocampus, as well as in the superior frontal gyrus and insula 
(Figure 17B). When the hippocampal cluster was extracted, AD subjects showed 
significantly lower GMD compared to both Aβ+ and Aβ- MCI and CN subjects (Figure 
17C). Aβ+ MCI subjects also had significantly lower GMD in this region relative to Aβ+ 
and Aβ- CN participants (Figure 17C). Similar results were observed with the 
parahippocampus, superior frontal gyrus, and insula (data not shown). No significant 
clusters were observed in the opposite direction (high plasma NFL associated with 
higher GMD). 
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Figure 15. VBM analysis of MRI and plasma tau in all participants.  
High plasma tau is correlated with low grey matter (GM) density in the (A) 
parahippocampus, (B) precuneus, (C) striatum, and (D) thalamus. C and D represent the 
anatomic overlap (orange) of regions of GM atrophy associated with increased plasma 
tau using only age, sex, APOE ε4 status, and total intracranial volume as covariates 
(yellow) and with the addition of diagnosis as a covariate (red). Results are displayed at 
p<0.001 (uncorrected) and at a threshold (k) of 100 voxels.  
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Figure 16. Mean grey matter density in all participants of the plasma tau study.  
Selected regions significant in the voxel-wise analysis across (A) diagnostic and 
(B) amyloid status. Covariates included in both models include age, sex, APOE ε4 
status, and total intracranial volume. Bars are mean ± standard error. CN = cognitively 
normal; MCI = mild cognitive impairment; AD = Alzheimer’s disease; AB- = amyloid-beta 
negative; AB+ = amyloid-beta positive. 
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Figure 17. VBM analysis of MRI and plasma NFL in all participants.  
(A) High plasma NFL was associated with low GMD largely in the frontal, 
temporal, insular, and occipital cortices, covaried for age, sex, education, APOE ε4 
carrier status, and total intracranial volume (ICV). (B) When diagnosis was also included 
as a covariate, high plasma NFL was associated with low GMD in more focal regions, 
including hippocampus, parahippocampus, insula, and superior frontal gyrus. (C) GMD 
in the right hippocampal cluster in (B) was significantly different between groups based 
on diagnosis and Aβ status (positive/negative; striped bars indicate Aβ-positive), with AD 
patients and Aβ-positive MCI showing the lowest GMD in this region. Results in (A) and 
(B) are displayed at p<0.05 (FWE corrected) and a minimum cluster size (k) of 100 
voxels. No significant clusters were observed in the opposite direction (high plasma NFL 
associated with more GMD).  
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Amyloid-positive Participants 
 There was no significant association between plasma tau and GMD in the Aβ- 
participants, however higher plasma tau was significantly correlated with lower GMD in 
the Aβ+ participants in the fusiform, hippocampus, parahippocampus, precuneus, and 
premotor cortex (Figure 18A-D, voxel-wise p<0.001 (uncorrected), k=100 voxels), as 
well as the frontal and parietal lobes, pre- and post-central gyri, and the globus pallidus. 
Notably, in the MTL cluster for MCI and AD, Aβ+ participants showed lower mean GMD 
compared to Aβ- participants (Figure 16B). After diagnosis was added as a covariate, 
many of the same regions of low GMD remained significantly correlated with higher 
plasma tau including in the precuneus, parahippocampus, and premotor cortex (Figure 
18B-D). No voxels, either with or without diagnosis as a covariate, survived correction for 
type I error rate. No significant clusters were observed in the positive/unexpected 
direction (data not shown). 
Similar to plasma tau, no significant association between plasma NFL and GMD 
was observed in Aβ- participants only. In Aβ+ participants, higher plasma NFL levels 
was associated with reduced GMD in the angular gyrus, supramarginal gyrus, 
dorsolateral prefrontal cortex, anterior prefrontal cortex, pre- and postcentral gyrus, 
middle temporal cortex, caudate, hippocampus, and parahippocampus (Figure 19A, 
voxel-wise p<0.05 (FWE corrected), k=100 voxels). When controlling for diagnosis, 
lower GMD in the right superior frontal gyrus and left precentral gyrus were associated 
with high plasma NFL (Figure 19B). Results were unchanged when APOE ε4 status was 
excluded as a covariate (data not shown). No significant clusters were observed in the 
opposite direction. 
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Figure 18. VBM analysis of MRI and plasma tau in amyloid positive participants.  
High plasma tau is correlated with low grey matter (GM) density in the (A) 
hippocampus, (B) precuneus, (C) parahippocampus, and (D) BA 6 premotor cortex. B-D 
also represent the anatomic overlap (orange) of regions of GM atrophy associated with 
increased plasma tau using only age, sex, APOE ε4 status, and total intracranial volume 
as covariates (yellow) and with the addition of diagnosis as a covariate (red). Results are 
displayed at p<0.001 (uncorrected) and at a threshold (k) of 100 voxels. 
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Figure 19. VBM analysis of MRI and plasma NFL in amyloid positive participants.  
(A) In Aβ-positive participants only, high plasma NFL was associated with low 
GMD in the temporal and parietal cortices, superior frontal gyrus, and hippocampus, 
covaried for age, sex, education, APOE ε4 carrier status, and total intracranial volume 
(ICV). (B) When diagnosis was included as an additional covariate, high plasma NFL 
was associated with low GMD in the right superior frontal gyrus and the left precentral 
gyrus. Results are displayed at p<0.05 (FWE corrected) and minimum cluster size (k) of 
100 voxels. No significant clusters were observed in the opposite direction (high plasma 
NFL associated with more GMD). 
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CSF-Plasma Tau Comparison 
Central (CSF) and peripheral (plasma) tau were significantly associated, 
although were not highly correlated in this subsample of participants (r = 0.232, 
p<0.001). Peripheral measures of tau protein were of total-tau only, thus, we sought to 
compare the regional atrophy associated with plasma tau to that associated with CSF t-
tau only. At p < 0.05 (FWE corrected), higher CSF t-tau was associated with lower GMD 
in the precuneus, temporal gyrus, and fusiform gyrus in all participants (Figure 20). 
However, the uncorrected results were used for comparison with the plasma tau results, 
as this threshold was used in the plasma tau analyses described above. Central and 
peripheral measures of tau protein were associated with GMD in some overlapping, but 
largely different brain regions. Across all participants, the temporal pole, fusiform, and 
angular gyrus were brain regions in which both higher CSF t-tau and plasma tau were 
associated with lower GMD (Figure 21). As several reports have previously shown, 
higher CSF t-tau was associated with lower GMD in cortical structures known to be 
affected in persons with AD. However, as above, in the present study plasma tau was 
predominantly associated with subcortical structures. Within the Aβ+ participants, no 
significant overlap was observed between the association of GMD with plasma tau and 
the association of GMD with CSF t-tau (data not shown). 
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Figure 20. VBM analysis of MRI and CSF total-tau in all participants.  
High CSF total-tau is correlated with low grey matter density in the (A-B) 
precuneus, (C) fusiform, and (D) BA21. Covariates included in the regression analysis 
were age, sex, APOE ε4 status, and total intracranial volume. Results are displayed at 
p<0.05 (FWE corrected) and at a threshold (k) of 100 voxels.  
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Figure 21. Anatomical overlap of grey matter density with plasma tau and CSF 
total-tau.  
Low grey matter density was associated with high plasma tau (blue) and high 
CSF t-tau (red) in some overlapping region (purple). Covariates included were age, sex, 
APOE ε4 status, total intracranial volume. Results are displayed at p<0.001 
(uncorrected) and at a threshold (k) of 100 voxels.  
  
 100 
CSF-Plasma NFL Comparison 
 Similar to the findings in Mattson et al., central (CSF) and peripheral (plasma) 
concentrations of NFL were highly correlated in this subsample of participants (r = 0.62, 
p<0.001). Across all participants, significant overlap was observed in the anatomical 
location of the associations between high levels of CSF NFL and low GMD and between 
high levels of plasma NFL and low GMD. Specifically, the overlap in association was 
largely observed in MTL regions (Figure 22A). When diagnosis was added as a 
covariate, overlap was only observed in the superior temporal cortex (BA22, Figure 
22B). In only the Aβ+ participants, a small amount of overlap was observed in the 
anterior temporal cortex (data not shown). When diagnosis was added as a covariate, no 
overlap was observed between the association of GMD with plasma NFL and the 
association of GMD with CSF NFL (data not shown). 
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Figure 22. Anatomical overlap of grey matter density with plasma NFL and CSF 
NFL in all participants.  
Low grey matter density was associated with high plasma NFL (red) and high 
CSF NFL (blue) in largely overlapping regions (purple). Covariates included were age, 
sex, APOE ε4, total intracranial volume. Analyses were run (A) with diagnosis, and (B) 
without diagnosis as an additional covariate. Results are displayed at p < 0.05 (FWE-
corrected) and at a threshold (k) of 100 voxels.   
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5.4 Discussion 
Plasma tau and NFL in AD quantified using the Simoa technique has only 
recently been investigated. The findings from these studies have been similar, with 
plasma tau and NFL significantly higher in AD compared to MCI and controls, but no 
significant difference between MCI and controls [128, 129, 218, 219]. However, there 
was high overlap in plasma tau and plasma NFL levels between these diagnostic groups 
which suggested they will not be a suitable biomarker for AD. Mattsson et al. (2016 and 
2017) also showed that higher plasma tau and NFL were associated with worsening 
cognition, atrophy, and hypometabolism over time suggesting evaluation of plasma tau 
may provide insight into brain changes over time [128, 129]. The main goal of this study 
was to determine how two markers of axonal neurodegeneration, tau and NFL, 
associated with neurodegeneration on a voxel-wise basis. Additionally, we investigated 
how peripheral and central measures of tau and NFL correlated with GMD. Both plasma 
tau and NFL were associated with cortical atrophy in a population at risk for AD or 
already manifesting signs of clinical AD.  
 
Plasma Tau Findings 
 We found high levels of plasma tau was correlated with low GMD in several AD-
specific brain regions, including the MTL and precuneus, as well as in the thalamus and 
striatum. Further investigation into only Aβ+ participants also revealed an association 
between higher plasma tau concentrations and lower GMD in MTL structures, the 
precuneus, and the premotor cortex. In Aβ- participants, no significant association 
between plasma tau and GMD was observed for any analysis. These findings suggest 
that plasma tau may reflect neurodegeneration in both AD-specific regions and more 
generally. Additionally, we failed to replicate the correlation of atrophy as measured by 
cortical thickness described by Dage et al. (2016) [218].    
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The MTL is one of the first brain regions that shows tau pathology and the 
earliest to degenerate in AD patients [86]. Thus, our observation that high plasma tau is 
associated with cortical atrophy in several MTL structures including the 
parahippocampus and hippocampus across all participants and in Aβ+ participants 
suggests that this peripheral measure of tau may be reflective of CSF and brain tau 
pathology as well as brain atrophy. Although a different method was used to investigate 
the brain integrity, our findings are similar to but not replicative of that of Dage et al. 
(2016) who showed higher plasma tau was associated with lower cortical thickness in 
the entorhinal, inferior temporal, middle temporal, and fusiform [218]. The mean plasma 
tau levels for MCI and CN were nearly equivalent in this study which could account for 
our failure to replicate. We also observed a correlation between higher plasma tau and 
lower GMD in the precuneus. A functional decline in the precuneus occurs early in the 
course of AD. Specifically, the precuneus along with the hippocampus are both core 
components of the default mode network, an important functional resting-state network 
that is impaired early in AD [228]. Thus, the atrophy in the precuneus associated with 
plasma tau could be reflective of structural deterioration in the default mode network 
early in AD.  
Even more striking was the inverse association of plasma tau with GMD in the 
thalamus and the striatum across all participants, especially given that these areas are 
affected later in the disease course. These were the only brain regions that were also 
independent of diagnosis, suggesting that plasma tau may reflect neurodegeneration 
unrelated to AD diagnosis, possibly due to normal aging. Studies evaluating plasma tau 
in other tauopathies may shed light on this hypothesis. Additionally, cholinergic neurons 
project to thalamic nuclei and high levels of acetylcholine are found in the striatum [229, 
230]. Tau protein may play a role in that loss of cholinergic neurons through a 
mechanism involving the interaction of extracellular tau with M1/M3 muscarinic receptors 
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present in the cholinergic neurons [231, 232]. This interaction between tau and 
muscarinic receptors may be a way, although not the only one, to explain the spreading 
of tau pathology occurring in AD. This interaction was mediated by soluble tau 
suggesting its association in the healthy brain, binding leads to an increase in calcium 
and thus cell death. Alternatively, in the Aβ+ participants, the association of plasma tau 
and GMD in the parahippocampus and precuneus was independent of diagnosis. These 
findings suggest that plasma tau may be reflecting neurodegeneration specific to AD 
pathology. 
Our initial hypothesis was that plasma tau and CSF t-tau would be related to 
similar regions of atrophy, especially if the two tau measures were truly reflective of AD 
neurodegeneration. Unexpectedly, plasma tau and CSF t-tau had very little overlap, with 
plasma tau mapping more to subcortical structures and CSF t-tau mapping more to 
cortical structures. Additionally, the CSF and plasma tau concentrations were not highly 
correlated, although significantly associated, suggesting the significance may be driven 
by the large sample size. Only small regions of overlap were observed in the temporal 
pole, fusiform, and angular gyrus. These results suggest that CSF and plasma measures 
of tau protein may reflect related but somewhat different pathological substrates of AD. 
This could be due to differences in the assays, tau isoforms detected by the assays, or 
in the variability of the measurements. There may also be differences in how tau, 
released from neurons, is cleared from brain interstitial fluid to CSF and plasma. 
Additionally, peripheral tau may be influenced by systemic tau since tau is expressed in 
regions outside of the brain, for example in the breast, skeletal muscle, testis, and colon. 
Further work is needed to further elucidate the differences between plasma and CSF 
tau. 
We have shown that plasma tau may be a non-specific marker for 
neurodegeneration. However, plasma tau may still be relevant to AD since we observed 
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associations of higher plasma tau with AD-specific brain atrophy in Aβ+ participants but 
not in Aβ- participants. Future replication and longitudinal studies will be important to 
fully elucidate the contribution of plasma tau as a possible biomarker in AD and other 
tauopathies. 
 
Plasma NFL Findings  
. High concentrations of plasma NFL were associated with low GMD in MTL 
regions and the insula, independent of diagnosis and after correction for multiple 
comparisons. No significant association between plasma NFL and GMD was observed 
in Aβ- participants; however, Aβ+ participants showed an association between high 
plasma NFL concentrations and low GMD in the hippocampus, although these findings 
were not independent of diagnosis. Plasma and CSF NFL concentrations also showed 
overlapping associations with GMD in the MTL. Our findings support plasma NFL as a 
peripheral biomarker associated with brain neurodegeneration. 
NFL is encoded by the neurofilament light chain polypeptide (NEFL) gene. NFL 
co-assembles with neurofilament medium (NFM) and neurofilament heavy (NFH) chain 
proteins to form intermediate filaments that run the length of the axon. Mutations in the 
NFL, NFM, and NFH genes have been found in Charcot-Marie-Tooth disease, 
Parkinson’s disease, and Amyotrophic Lateral Sclerosis, respectively [233-235]. While 
NFL is mainly expressed in large-caliber myelinated axons, it has been found in neurites 
of the CNS and other tissues such as endocrine, kidney, muscle, testis, and spleen 
[236]. Knockout NFL mice develop normally, similar to tau knockout mice, but a 20-fold 
reduction in NFM and NFH were reported along with a decrease in the number of 
myelinated axons [237]. Additionally, transgenic mice expressing APP/PS1 (AD mouse 
model) mutations with the NFL knockout showed increased Aβ deposition, dystrophic 
neurites, microgliosis, and synapse vulnerability [238]. These studies suggest that NFL 
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is important for neural integrity and potentially how abnormal functioning might lead to 
disease. 
Post-mortem immunohistochemical analysis has shown increased NFL in the 
hippocampus of AD patients relative to controls [239]. Our voxel-wise analysis of plasma 
NFL with GMD support these findings, as well as the findings by Mattsson et al. (2017) 
[129]. Mattsson et al. (2017) reported high plasma NFL was associated with a decline in 
hippocampal volume over time. Although our analysis was cross-sectional, our voxel-
wise analysis showed high plasma NFL was associated with reduced hippocampal 
GMD. This association may represent a pattern of normal aging considering these 
findings are independent of diagnosis. While studies investigating plasma NFL in older, 
cognitively healthy adults have yet to be reported, a study showed CSF NFL predicted 
higher hippocampal atrophy in cognitively normal, older adults [240]. Since plasma and 
CSF NFL are highly correlated, it is likely that this association would also be observed 
with plasma. However, no association of plasma NFL in the CN group was observed in 
our study (data not shown). Instead, hippocampal GMD was lowest in AD, followed by 
MCI Aβ+ participants suggesting that plasma NFL may reflect disease-associated 
neurodegeneration.  
An inverse correlation between high plasma NFL and low GMD in the 
hippocampus in Aβ+ subjects was also observed, although this association was not 
independent of diagnostic status. Our results also indicate that APOE ε4 status did not 
have a significant effect on atrophy in this group. Those who are Aβ+ are at higher risk 
for AD further supporting that plasma NFL may be capable of detecting neural injury in a 
disease-specific group. Plasma NFL was not significantly associated with 
neurodegeneration in the Aβ- subjects, even when a less-stringent, uncorrected p-value 
was used (data not shown). These findings support the notion that neuronal injury is not 
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associated with plasma levels in early stages, perhaps because it is not extensive in the 
preclinical stage [241].  
Plasma and CSF levels of NFL are highly correlated and associated with AD, 
Parkinson disease, progressive supranuclear palsy, and degeneration mediated by HIV-
infection, suggesting plasma NFL may be a suitable non-invasive biomarker for neural 
injury [126, 129, 130, 242]. Our initial hypothesis was that plasma NFL and CSF NFL 
would be related to similar regions of atrophy, especially since the two measures of NFL 
were highly correlated. As expected, high central and peripheral concentrations of NFL 
were associated with low GMD in largely overlapping brain regions, particularly in the 
MTL. These results suggest that CSF and plasma measures of NFL protein may be 
reflecting related pathological substrates of axonal degeneration. As discussed earlier in 
this section, NFL is expressed in the peripheral nervous system and non-neural tissues 
[236]. The concentration of NFL in plasma and CSF were highly correlated in this cohort 
and were associated with neurodegeneration in largely overlapping regions, suggesting 
that these two markers of NFL are likely reflecting injury specific to the central nervous 
system. 
Mattsson et al. (2017) also reported plasma tau was a weaker biomarker for 
axonal degeneration compared to plasma NFL [129]. Recently, our group reported the 
association of plasma tau with neurodegeneration on MRI [243]. We observed an 
observation between higher plasma tau and low GMD in predominantly subcortical 
structures of the brain. This anatomical distribution was strikingly different from 
comparison of CSF tau and GM, which mapped mainly to cortical structures 
(Supplemental Figure). While we did not directly compare the plasma NFL with plasma 
tau in the current study, we did a visual comparison of the two markers and their 
association with GMD. While both plasma NFL and tau were inversely correlated with 
GMD, several differences were noted. First, the association between plasma NFL and 
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GMD survived correction for Type I error (FWE correction for multiple comparison) while 
the plasma tau analysis did not. The robust association of plasma NFL with GMD 
suggests that it may be a better peripheral marker for neurodegeneration than plasma 
tau. Furthermore, the concentration of plasma and CSF NFL are highly correlated and, 
plasma and CSF NFL were associated with atrophy in overlapping brain regions, while 
the plasma and CSF tau showed vastly different associations with GMD. These findings 
further suggests that plasma NFL may be a more suitable peripheral marker for brain 
neurodegeneration, as it likely measures a similar pathological substrate as CSF NFL. 
 
Study Limitations 
One study limitation is the lack of a commensurate replicate data set. This tau 
and NFL quantification method is relatively new and hopefully independent data sets will 
become available. Additionally, accumulated p-tau is the main hallmark in AD and other 
tauopathies but there is not yet a technique for measuring p-tau in plasma, thus yielding 
a second limitation to this study. New techniques to assess p-tau in plasma could be 
extremely beneficial. A third limitation is that our data is cross-sectional only. 
Longitudinal plasma tau and NFL data would provide us the information needed to better 
assess changes in plasma tau over time and the association between changing plasma 
tau measures and rate of neurodegeneration. Next, we excluded participants with 
plasma tau values below the lower limit of quantification, although the results were not 
significantly different when these participants were included (data not shown). Lastly, the 
plasma NFL study had more participants relative to the plasma tau study, thus we did 
not do a direct analytical comparison but a visual comparison of the two markers and 
their association with neurodegeneration. 
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Summary 
In conclusion, high concentrations of plasma tau and plasma NFL were 
associated with lower GMD. However, plasma NFL had a more robust association with 
neurodegeneration and may by a better peripheral marker for neural injury. Taking into 
account these findings and those described by Mattsson et al. (2016, 2017), we believe 
plasma tau and plasma NFL may be useful as a screening tool for detecting early AD-
related neurodegeneration, rather than as a diagnostic tool per say [128, 129].  
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Chapter 6: The Tau Biological Network 
6.1 Introduction 
With the marked heterogeneity observed in sporadic tauopathies, no single 
candidate gene or protein is likely the ultimate cause of disease. Developing new 
approaches to determine the genetic contribution to complex diseases have been a 
major area of study. GWAS, polygenic risk score, gene expression analysis, and whole-
exome or whole-genome sequencing are some of the tools currently used to better 
understand genetics and disease [244-246]. However, current approaches often fail to 
take into account the interaction between different molecules and genes; thus, another 
analytical approach is needed. One approach to overcome these issues involves 
investigating the physical and functional interactions of molecules and evaluating the 
effect of these interactions on risk for complex diseases, such as Alzheimer’s disease 
(AD). Genes, their protein products, and the interactions they have with other molecules 
is called a “biological network” [247, 248]. The interactions in the biological network can 
be protein-protein, gene-gene, gene-protein, protein-DNA, or protein-RNA. The aberrant 
function of one or more molecules in the biological network could potentially lead to 
abnormal function of a molecule up- or downstream of that signal.  
Biological networks can be curated using different methodologies, both a 
posteriori and a priori. For example, information for networks can be obtained a 
posteriori from assays such as yeast two-hybrid, which is used to detect protein-protein 
interactions, or microarray gene expression data used to detect functional relationships 
between gene transcripts [249, 250]. Additionally, statistical and computational methods 
can be utilized to predict or infer gene networks from existing data [251]. Another way to 
construct a biological network is to use a priori knowledge from network databases or 
reported associations in the literature to build a network of interest [252].  
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Several networks are currently defined such as co-expression, gene regulatory, 
signaling, or metabolic networks. Our goal was to develop a special network, one 
focused on the biology of the tau protein, the major pathogenic protein in tauopathies. 
Tau can undergo several modifications through interactions with a complex network of 
proteins (“the tau biological network”). As discussed in Chapter 1, although we do not 
know the exact cause of cause tau aggregation, dysfunction related to these 
modifications are likely to cause conformational changes, hyperphosphorylation and 
other post-translational modifications, and aggregation, ultimately culminating in tau 
pathology. One example of a functional interaction of molecules in the tau biological 
network is seen between O-GlcNAc and phosphorylation. O-GlcNAc glycosylation of tau 
occurs when O-GlcNAc is attached to phosphorylation sites on tau, competing with 
phosphate groups. Indeed, an inverse correlation has been observed between O-
GlcNAc glycosylation and phosphorylation, with O-GlcNAc glycosylation reduced in AD 
post-mortem brain samples [253]. Increased O-GlcNAc could potentially inhibit tau 
hyperphosphorylation and reduce tau aggregation. However, the reason for the 
reduction in O-GlcNAc glycosylation in AD is unknown. Investigation of genetic variation 
surrounding the gene that codes for O-GlcNAc and its interacting partners may provide 
clues as to the underlying causes of the reduction observed in AD brain. 
Genetic variations that alter coding and expression of proteins within the tau 
biological network may have a significant impact on the pathological processing of tau 
and thus, are an important and under-explored area of study. Further investigation into 
the tau biological network may provide insights into molecular mechanisms and 
pathways that may contribute to AD and other tauopathies. Thus, our goal is to develop 
a tau biological network from proteins and genes involved in the various processes 
governing tau processing and function as described in Chapter 1.  
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6.2 Curating the Tau Biological Network 
We took an a priori approach to curate the tau biological network. First, genes 
and proteins associated with the search term “MAPT” or “tau protein” were collected 
from the following databases: GeneMania, BioGrid, IMP Princeton, STRING, and Gene 
Ontology [254-258]. Next, we did a PubMed search using the search terms “MAPT”, 
“tau”, and “neurofibrillary tangles” in combination with one or more category/subcategory 
listed in Table 9. Identified genes include those with physical and/or functional 
interactions with MAPT or the tau protein, in addition to genes identified by GWAS, 
candidate gene, or association studies. Genes associated with MAPT or tau were 
organized by category and subcategory, along with one or more literature reference(s) 
supporting the association. An example of this organizational scheme is shown in Table 
10. Some genes belonged to more than one category, resulting in inclusion of multiple 
listed categories (Table 10).  
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Table 9. Search terms for curating the tau biological network. 
Category Subcategory  
DNA/RNA and protein 
processing 
translation 
alternative splicing 
gene expression 
post-translational modifications 
other 
trafficking/sorting 
axonal transport 
golgi appartus 
endoplasmic reticulum 
secretion 
clathrin 
endocytosis 
endosome 
other 
clearance and 
degradation 
proteasome 
autophagy 
blood-brain barrier 
CSF absorption 
ISF bulk flow 
microglia 
other 
mediator of tau 
toxicity 
mitochondria 
Aβ toxicity 
calcium influx 
other 
cellular functions 
vesicle trafficking 
neuronal polarity 
microtubule stability 
other 
  
  
1
1
4
 
Table 10. A brief example of the tau biological network results. 
 
Gene Gene Name Chr category subcategory 2nd category PubMed ID GWAS 
BIN1 bridging integrator 1 2 Trafficking/sorting clathrin mediator of tau toxicity 23399914 Y 
PICALM 
phosphatidylinositol binding 
clathrin assembly protein 
11 Trafficking/sorting clathrin  25241929 Y 
DRP1 dynamin-related protein 1 12 Mediator of tau toxicity mitochondria  28173111  
PIN1 NIMA-interacting 1 19 Mediator of tau toxicity other  10391244  
GSK3B glycogen synthase kinase 3 beta 3 Processing PTM  14690523  
OGT O-GlcNAc transferase X Processing PTM  27126545  
TREM2 
triggering receptor expression 
on myeloid cells 2 
6 Clearance/degradation microglia  26364736  
TRIM46 tripartite motif-containing 46 1 Cellular function neuronal polarity  26671463  
 
Gene = gene symbol; Chr = chromosome number; GWAS = genome wide association study; PTM = post-translational 
modification; Y = yes. 
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6.3 Utilization of the Tau Network 
A biological network centered on tau, or any disease-associated protein, has a 
plethora of research potential. One of the major benefits of a tau biological network is to 
improve our understanding of the role of genetics in modulating abnormal tau processing 
and aggregation, especially in sporadic tauopathies. As discussed in Chapter 1, we still 
have much to learn regarding the physiological and pathophysiological functions of tau. 
Further investigation into genetic and protein interactions that produce an increase in 
pathological tau could aid in predicting disease risk. Further, a better understanding of 
the underpinnings regarding physiological tau could provide insight into alternative 
pathways or signaling cascades that may be altered in disease. 
Additionally, genetic variation within the tau network could be evaluated for 
association with disease phenotypes such as cognition or neuroimaging or fluid 
biomarkers. The genetic variation-phenotype association can be investigated using the 
entire network, similar to a set-based analysis, or using an epistatic association analysis. 
Results from these analyses may help explain the genotype-phenotype connection in 
complex diseases, such as AD, since it is likely that that multiple genes with small effect 
sizes contribute to overall disease risk, perhaps even in a synergistic way. Furthermore, 
having access to a tau network could aid in the identification of new molecular pathways 
associated with disease. Ultimately, fully investigating and understanding the tau 
biological pathway could lead to a more reliable biomarker for diagnosis, identification of 
potential novel drug targets for a better treatment, and could help explain to similarities 
and differences between tauopathies.  
Another possible outcome from research utilizing a tau network is identification of 
disease-related subnetworks. Analyzing proteins that interact with tau to enhance 
phosphorylation, for example, could identify a previously unknown molecule that effects 
tau phosphorylation state. Any identified molecule could have a direct impact or be from 
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a neighboring network indicative of a more complex pathway affecting tau 
phosphorylation. This type of analysis could also help with further classification of 
diseases involving tau. For example, a set of genetic interactions in the network may be 
associated with disease state or a specific disease phenotype in a subset of patients. 
This could help in development of a personalized treatment for AD and other 
tauopathies.  
There are limitations in using a hand-curated network. First, lists that are hand-
curated are rarely exhaustive. In addition, since the network is based on previously 
identified associations, some of the included/excluded molecules could come from 
assays that were false positives/negatives. Regardless, it is unlikely that any 
methodology used for building a network will be completely inclusive. However, the 
composition of a tau biological network provides a starting point for new investigation 
into the genetic contributions to various tauopathies. 
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Chapter 7: Summary and Future Directions  
 Tauopathies encompass a number of familial and sporadic neurodegenerative 
diseases associated with tau pathology. In this report, we used PET imaging to identify 
disease-specific metabolic patterns for two forms of familial tauopathy. Additionally, we 
investigated the association of plasma tau and NFL, two axonal degeneration markers, 
with neurodegeneration on MRI. Finally, we hand-curated a tau biological network to 
investigate the genetic contribution to tauopathies. 
7.1 Glucose Metabolism in Alzheimer’s Disease 
 Extensive work has been done investigating the metabolic pattern in AD and how 
[18F]FDG uptake is associated with AD-associated phenotypes. Chapter 2 provides a 
brief overview of the current state of the knowledge regarding [18F]FDG PET across the 
AD spectrum. In general, hypometabolism is observed in AD in the temporoparietal 
cortex, medial temporal lobe (MTL), posterior cingulate, and precuneus, with frontal 
involvement in more advanced AD. MCI subjects usually show hypometabolism in 
similar regions to AD, although to a lesser extent, suggesting that [18F]FDG PET may be 
useful for the tracking the progression of disease. Indeed, several studies have shown 
reduced [18F]FDG uptake in AD-specific regions in MCI converters relative to MCI non-
converters. This AD-specific pattern of hypometabolism also helps differentiate AD from 
clinically similar neurodegenerative diseases. Hypometabolism observed in cognitively 
normal individuals is usually associated with advancing age. Changes in glucose 
utilization were also found to mirror the cognitive decline occurring during disease 
progression, which further supports the use of [18F]FDG PET in the clinical diagnosis of 
AD and in research.  
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7.2 Glucose Metabolic Patterns in Multiple Systems Tauopathy with Presenile Dementia 
 Chapter 3 investigates glucose metabolism in participants with multiple systems 
tauopathy with presenile dementia (MSTD), a form of frontotemporal dementia with 
parkinsonism-17 with tau inclusions (FTDP-17T), caused by an (a) to (g) transition at 
position +3 of intron 10 of the microtubule associated protein tau (MAPT) gene. The 
mutation causes overexpression of 4 repeat (4R) tau isoforms with increased 4R/3R 
ratio leading to neurodegeneration. Clinically, these patients primarily present with 
behavioral variant frontotemporal dementia (bvFTD), showing disinhibition, disordered 
social comportment, and impaired executive function, memory, and speech. While 
altered glucose metabolism has been reported in subjects with sporadic bvFTD, it has 
yet to be investigated in an FTDP-17 sample of this size. In this study, eleven mutation 
carriers and eight non-carriers in the MSTD family were imaged using [18F]FDG PET. 
Eight of the MAPT intron 10 +3 mutation carriers met diagnostic criteria for bvFTD 
(symptomatic carrier), while three MAPT intron 10 +3 carriers were not cognitively 
impaired (asymptomatic carrier) at the time of the [18F]FDG PET scan. Images were 
assessed on a voxel-wise basis for the effect of mutation carrier status. Compared to 
non-carriers, MAPT intron 10 +3 mutation carriers showed lower [18F]FDG uptake 
bilaterally in the MTL and parietal and frontal cortices. Anatomical changes measured 
from magnetic resonance imaging (MRI) were predominantly seen bilaterally in the MTL 
areas and substantially overlapped with the regions identified as hypometabolic. Further, 
these atrophic and metabolic changes overlap previously described patterns of 
neurodegeneration in MSTD patients and are consistent with the characteristics of their 
cognitive dysfunction. Furthermore, asymptomatic carriers showed hypometabolism and 
atrophy in the MTL suggesting these changes precede clinical onset. This is similar to 
that observed in MCI and AD as discussed in Chapter 2. However, these findings are in 
contrast to those observed with the GSS F198S mutation, which show hypermetabolism 
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in disease-specific regions in asymptomatic carriers, as described in section 4.3. Overall, 
these results suggest that neuroimaging can describe the neuropathology associated 
with this MAPT mutation. 
 
Future Directions 
One area of interest is further determining the different functional and structural 
changes in the asymptomatic carrier group relative to the symptomatic and non-carrier 
participants and track their progression over time. For the current study, only three 
asymptomatic carriers were available for analysis, precluding voxel-based analysis. 
Increasing the sample size and collecting longitudinal MRI and [18F]FDG PET imaging in 
this family may help resolve this question and allow for a better investigation of the 
temporal relationships of structural and functional changes in MSTD. Furthermore, 
investigation of this family with tau PET is warranted to track the progression of tau 
pathology in vivo as discussed in section 1.4. This information could also be used to 
compare the difference in the progression of tau pathology during the disease course of 
different classes in tauopathies, including MSTD. Finally, it would also be interesting to 
determine if metabolic changes in the brain are associated with clinical presentations of 
disease, such as differences between those who present with cognitive or behavioral 
changes only versus those who also have motor abnormalities. 
 
7.3 Amyloid and Glucose Metabolism in Gerstmann–Sträussler–Scheinker Disease 
Chapter 4 assesses brain glucose metabolism and amyloid deposition in a prion 
protein disease. First, we investigated glucose metabolism in Gerstmann–Sträussler–
Scheinker Disease (GSS) subjects with the F198S mutation. GSS F198S is a familial 
neurodegenerative disorder characterized clinically by ataxia, parkinsonism, and 
dementia, and neuropathologically by deposition of amyloid plaques composed of prion 
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protein (PrP) and neurofibrillary tangles composed of hyperphosphorylated tau protein. 
Twelve GSS F198S mutation carriers and ten non-carriers were imaged using [18F]FDG 
PET. Images were then assessed on a voxel-wise basis for the effect of clinical 
diagnosis and mutation carrier status. At the time of the scan, eight GSS F198S 
mutation carriers were symptomatic (symptomatic carriers (SC)), showing signs of motor 
and cognitive impairment or dementia, and four GSS F198S mutation carriers were 
asymptomatic (asymptomatic carriers (AC)). SCs showed lower glucose metabolism in 
the left caudate head and bilaterally in the putamen compared to ACs and non-carriers 
(NCs), and bilaterally in the cerebellum compared to NCs. ACs showed 
hypermetabolism in the left caudate head and putamen compared to NCs suggestive of 
increase in energy demands or compensation for dying neurons. Considering the 
hypermetabolism occurs prior to clinical symptoms and in the same brain regions which 
later show hypometabolism suggests that we may be capable of detecting functional 
brain changes early in the disease course. However, this is different than what was 
observed in AD and the MSTD family. Considering both AD and GSS are secondary 
tauopathies with biochemically and structurally indistinguishable neurofibrillary tangles, 
with amyloid being the primary pathology, these increased glucose metabolism before 
clinical onset may indicate a more dynamic relationship between amyloid pathology, the 
brain region affected, and age. Overall, these findings suggest that hypometabolism in 
the cerebellar and striatal regions may partially underlie motor and cognitive dysfunction 
in GSS F198S patients. This may be preceded by hypermetabolism, which could serve 
as an early prognostic marker.  
This chapter also evaluated if [11C]Pittsburgh Compound B (PiB) PET is capable 
of detecting APrP in PRNP gene carriers. Six individuals at risk for GSS and eight 
controls underwent [11C]PiB PET scans using standard methods. Approximately one 
year after the initial scan, each of the three asymptomatic carriers (two with PRNP 
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P102L mutation, one with PRNP F198S mutation) underwent a second [11C]PiB PET 
scan. Three P102L carriers, one F198S carrier, and one non-carrier of the F198S 
mutation were cognitively normal, while one F198S carrier was cognitively impaired at 
the time of the study. No [11C]PiB uptake was observed in any subject at baseline or at 
follow-up. Neuropathologic study of the symptomatic individual revealed PrP-
immunopositive plaques and tau-immunopositive neurofibrillary tangles in cerebral 
cortex, subcortical nuclei, and brainstem. PrP deposits were also numerous in the 
cerebellar cortex. This finding suggests that [11C]PiB PET is not suitable for in vivo 
assessment of APrP plaques in patients with GSS. 
 
Future Directions 
 As described in section 1.4, radiotracers for pathological tau have been 
successfully used in tauopathies and cognitively normal adults. Considering tau tangles 
in GSS F198S are biochemically and structurally indistinguishable from those seen in 
AD, it would be interesting to observe tau deposition in vivo in this kindred. I would 
particularly be interested in observing the association of in vivo tau pathology with 
disease progression, cognitive status, and motor function. Additionally, investigating the 
structural and functional connectivity using diffusion tensor imaging and resting-state 
functional MRI could provide clues as to how aberrant connectivity is related to the GSS 
F198S mutation. It would also be interesting to determine if the hypermetabolism in the 
AC group was dependent on amyloid or tau deposition in the same regions. However, 
one challenge with these studies is recruiting an increased number of participants, as 
the number of living members of the family are limited. Another future direction would be 
to sequence the MAPT gene in the GSS F198S subjects to investigate the impact of 
MAPT genetic variation on neuroimaging phenotypes and determine if there are any 
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similarities of MAPT variation contributing to clinical outcome measurements in 
participants with GSS and other tauopathies. 
 
7.4 Association of Tau and Neurofilament Light Chain with Grey Matter Density 
Chapter 5 examines how two peripheral markers of axonal degeneration, plasma 
tau and neurofilament light (NFL), were correlated to grey matter density (GMD) on MRI 
on a voxel-by-voxel basis in healthy, cognitively normal elderly adults (CN) and 
participants with mild cognitive impairment (MCI) or Alzheimer’s disease (AD). The 
association of plasma tau and plasma NFL with GMD were also compared with the 
association of central (cerebrospinal fluid, CSF) measures of tau and NFL with GMD. 
Baseline MRI scans, plasma and CSF tau, and plasma and CSF NFL were evaluated to 
determine their association with GMD. High levels of both plasma tau and NFL were 
associated with low GMD across all participants.  
For plasma tau, high concentrations were negatively correlated with GMD in the 
medial temporal lobe (MTL), precuneus, thalamus, and striatum. The associations with 
thalamus and striatum were independent of diagnosis suggesting that plasma tau may 
reflect neurodegeneration unrelated to AD diagnosis, possibly due to normal aging. 
Furthermore, these findings suggest that the association between plasma tau and low 
GMD in the MTL and precuneus may be a diagnostic effect. Alternatively, in the Aβ+ 
participants, the association of plasma tau and GMD in the parahippocampus and 
precuneus was independent of diagnosis. Plasma tau may reflect AD-specific 
neurodegeneration in a specific population. The association of AD-specific brain regions 
in a population at high risk for AD (Aβ+ subjects) also supports the use of combining 
multiple biomarkers to identify higher risk patients for disease. When compared to CSF 
total-tau, plasma tau showed a notably different associated brain atrophy pattern, with 
only small overlapping regions in the fusiform gyrus. Plasma tau mapped predominantly 
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to subcortical regions, while CSF total-tau mapped mainly to cortical regions. These 
results demonstrate that central and peripheral measures of tau protein may reflect 
different pathologies. Additionally, peripheral tau may be influenced by systemic tau 
outside the brain, such as that in the liver or testis. Overall, plasma tau may serve as a 
non-specific marker for neurodegeneration but is still relevant to AD considering low 
GMD was associated with plasma tau in Aβ+ participants and not in Aβ- participants. 
For plasma NFL, an inverse correlation was observed between plasma NFL and 
GMD. High plasma NFL was associated with widespread, lower GMD in the frontal, 
temporal, insular, and occipital cortices. When diagnosis was added a covariate, high 
plasma NFL was still correlated with lower GMD in the hippocampus, parahippocampus, 
insula, and superior frontal gyrus suggesting concentrations of plasma NFL may be 
sensitive to neurodegeneration in AD-specific regions. Across Aβ+ subjects, high plasma 
NFL was associated with low GMD in the hippocampus and superior frontal gyrus when 
diagnosis was not entered as a covariate. When diagnosis was added as a covariate, 
the signal remained in the superior frontal gyrus and inferior parietal lobe. However, no 
significant clusters were observed in the Aβ- subjects or in the CN group alone 
suggesting that the neurodegeneration associated with NFL levels may not be 
measurable in the preclinical stage of disease. Plasma and CSF NFL were highly 
correlated. When we compared the associations of plasma NFL and CSF NFL with 
neurodegeneration, the two markers almost completely overlapped in their association 
with GMD. Large overlap was mainly observed in the MTL and insula. These results 
support the quantitative analysis that central and peripheral concentrations of NFL 
protein are closely correlated and may be reflecting similar pathological substrates of 
disease. Overall, our findings support plasma NFL as a peripheral biomarker associated 
with neurodegenerative disease. 
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In general, plasma NFL appeared to be a more specific marker for 
neurodegeneration than plasma tau. First, since CSF is considered a more accurate 
reflection of the biochemical composition of the brain, a good peripheral biomarker would 
show high association between CSF and plasma measurements, especially if we expect 
peripheral protein markers to accurately reflect brain injury. Reports by Mattsson et al. 
(2016, 2017) and in our subset of subjects, CSF and plasma NFL were highly correlated 
while CSF and plasma tau were not [129]. This was corroborated by our voxel-wise 
findings on MRI in which plasma and CSF NFL were associated with neurodegeneration 
in overlapping regions. Alternatively, plasma and CSF tau showed markedly different 
patterns of association with structural integrity. Finally, the plasma and CSF NFL findings 
survived FWE correction for type I error and the plasma and CSF tau findings did not, 
suggesting that plasma NFL has a stronger association with atrophy than plasma tau. 
Ultimately, these findings suggest that central (CSF) and peripheral (plasma) measures 
of NFL are measuring the same species of NFL result from brain neurodegeneration, 
and thus, may be a good biomarker for disease. Future studies are needed to confirm 
this theory.  
 
Future Directions 
Considering that plasma and CSF tau were associated with different patterns of 
neurodegeneration, further work is needed to further elucidate the differences between 
these measures of tau. Future replication and longitudinal studies will be important to 
fully elucidate the contribution of plasma tau as a possible biomarker in AD and other 
tauopathies. It would also be interesting to determine if plasma tau and plasma NFL may 
be useful together to predict future cognitive decline and increased longitudinal atrophy, 
and if the two protein markers are similarly or differently associated with cerebral plaque 
and neurofibrillary tangle deposition. Additionally, future studies in which plasma tau and 
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plasma NFL could be used in combination with other biomarkers to predict conversion or 
in a staged approach would be of interest. Since the plasma tau and plasma NFL assays 
are a relatively non-invasive and inexpensive test that could potentially be done in 
primary care rather than specialist settings, this technique could serve as a first-line 
screening tool to detect changes in asymptomatic older individuals and select individuals 
for more expensive or invasive (e.g. imaging, CSF) tests to more specifically identify AD-
based pathology. Another avenue to explore is the use of the tau biological network 
(described in Chapter 6 and section 7.5) to see if new biomarkers interact with any 
genes within the network and determine how these associations might be related to tau 
pathology. 
 
7.5 Building a Tau Biological Network 
 In Chapter 6, the methodology and use of a hand-curated tau biological network 
from gene and protein databases and a literature search was described. Aggregation of 
the microtubule associated protein tau is a major component of neurodegenerative 
tauopathies. Reports of genetic associations between the tau gene (MAPT) and 
neurodegenerative disease are inconsistent, therefore more research is needed to clarify 
the contribution of MAPT to sporadic tauopathies. Tau can undergo several 
modifications through interactions with a complex network of proteins. Genetic variation 
in genes encoding proteins in the tau biological network are hypothesized to significantly 
influence: (1) the mechanism and rate of tau accumulation in disease and (2) alternative 
splicing of MAPT. Abnormal accumulation of tau may be modulated by other proteins 
that interact to enhance or suppress its normal function. Manual curation of a list of 
genes with a priori knowledge of their possible association with the production of 
pathological tau may provide insight into molecular mechanisms and pathways 
governing aberrant tau aggregation. Integrating and analyzing genes with a physical or 
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functional impact on tau could present new hypotheses to explore regarding the etiology 
of complex diseases or factors that may be influencing disease phenotype.  
 Thus far we have identified over 150 genes that are related to tau or MAPT 
processing, trafficking, sorting, clearance, degradation, mediator of toxicity, and cellular 
functions were identified. Overall, development and utilization of the tau biological 
network will improve our understanding of the role of genetics in modulating abnormal 
tau processing and aggregation in disease, facilitating early diagnosis, novel drug 
development, and personalized treatment. 
 
Future Directions 
 The development of a tau biological network creates a number of opportunities 
for studying the genetic contribution of complex diseases. First, I would like to explore a 
gene-set analysis and investigate epistatic interactions using the tau network. 
Specifically, I would like to determine if genetic variation within the network is associated 
with deleterious or protective effect with disease-related phenotypes such as tau 
pathology. Second, I would like to pursue the creation of a tau polygenic risk score. 
Creating a score to summarize the genetic effects of markers associated with tau 
processing, function, and stability could provide a unique way to investigate the genetic 
contribution to tauopathies. Additionally, network information could be used to 
investigate the relationship of tau pathology with other factors in disease such as 
inflammation or neurodegeneration in non-neuronal cells in the brain (astrocytes, 
oligodendrocytes, microglia).  
 
7.6 Conclusion 
 Herein, we discuss the role of neuroimaging, genetics, and biomarkers in better 
understanding the underlying brain changes in tauopathies. First, glucose metabolism is 
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reduced in tauopathies, with hypometabolic patterns in brain regions that underlie the 
cognitive and/or motor function of disease. Some differences in glucose utilization may 
even be observed before clinical onset. Second, plasma NFL may more accurately 
represent neurodegeneration in the brain relative to plasma tau, making it a potential 
non-invasive and inexpensive peripheral biomarker for disease. Lastly, curation of a tau 
biological network may identify proteins that play an important role in the pathogenesis 
of tau pathology and disease. Thus, using a combination of techniques to help model the 
emergence and progression of tau pathology and its physiology and behavior will help 
us to gain a better understanding of the importance of different patterns of tau pathology 
in a number of different tauopathies. Ultimately, these combinations may help us to 
develop more sensitive biomarkers for early detection, identify novel targets for effective 
drug development, and provide accurate and sensitive diagnosis and disease tracking 
including using personalized diagnostics and therapeutics.  
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